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CLINICAL METABOLOMICS: AN OVERVIEW
Metabolomics is an example of a modern multidisciplinary research area. It has its roots 
in the technological revolutions of the sixties, the impressive breakthrough of the computer 
industry of the seventies and the re-birth of the holistic views in biology triggered by such a 
major undertaking as the human genome project. Metabolomics is a post-genomic discipline 
aiming at the study of metabolites: the end points and the intermediate products of the 
metabolism. Historically, the understanding of intracellular metabolic pathways and fluxes 
in model (mostly unicellular) organisms has been a dominant trend in the field [1]. However, 
clinical metabolomics, which has emerged as a spin-off of the ‘mainstream application’, 
focuses on the research of the metabolic regulation of the entire human organism and aims 
at the development of novel diagnostic/prognostic tools, prediction of patients responses to 
the treatment, exploration of the human metabolic individuality et cetera. Metabolomics of 
model systems and clinical metabolomics use the same analytical strategies but they differ 
with regard to experimental design and data treatment/interpretation.
Clinical metabolomics relies on the analysis of body fluids as the main source of 
information. The metabolic composition of the various body fluids provides the most 
accurate description of the individual physiological phenotype and as such is an essential 
element in the development of the concept of personalized medicine, the prediction of the 
susceptibility of an individual to a disease, the prediction of a state of disease or/and the 
outcome of a treatment. In a way, the most immediate goal of the clinical metabolomics is 
to reach the level of the technical confidence for being accepted as an independent measure 
in epidemiological studies.
Indeed, classical epidemiology operates within a limited space of clinical measures/
readouts while metabolomics-based ‘molecular epidemiology’ is contributing by bringing 
in a comprehensive description of the chemical phenotype. Thus, instead of linking pre-
existing knowledge to a certain level of the biological regulation (genes, gene expression 
protein expression), metabolomics offers a transverse approach to the problem evaluating the 
global outcome without taking into account the effect of any single variable. 
At the time when metabolomics was just an emerging area, many studies were logically 
focused on revealing the potential of various analytical techniques and of the data processing. 
At the current state-of-art, metabolomics studies do not only provide class separation (e.g. 
diseased versus controls, response to a therapy and/or disease progression) but also a critical 
identification of those metabolites involved in the separation and their role in a meaningful 
biological context which can be used for further validation.
The metabolomics approach has been extensively used in the profiling of cancer 
phenotypes with the main intention to provide a valuable tool for highly needed alternative, 
earlier and molecule-based detection methods. A big portion of the present studies is 
dedicated to rapid diagnosis and monitoring of therapy. Probably, breast cancer represents 
the best example of metabolomics applied to diagnostic purposes: this tumor type showed 
at tissue level an elevated phosphocholine level, low glycerophosphocholine and low glucose 
compared with healthy tissue or benign tumors which allowed differentiation with a 
sensitivity of the 83% and a specificity of 100% [2]. Furthermore, it was calculated that 
magnetic resonance spectroscopic imaging analysis performed on choline-positive tissues 
could have prevented a biopsy in 66% of the cases [3]. Metabolite profiling has also 
contributed to the research of early diagnostic markers in lung cancer which, according to 
the World Health Organization, kills more than any cancer – a situation that is estimated 
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to continue till 2030. For this pathological condition, standard screening methods such as 
chest radiography and sputum histology have not increased the survival rate [4]. However, 
it has been proved that high risk cytochrome p450 genotypes may accelerate the catabolism 
of naturally occurring volatile organic compounds (VOCs) in the breath of lung cancer 
patients. Metabolite-based detection techniques have pointed at alkanes, alkenes and 
benzene derivatives in the classification of lung cancer patients’ breath [5-7]. The additional 
investigation of body fluids showed an increased concentration of two aldehydes –hexanal 
and heptanal– in blood [8].
Among all the clinical conditions, infectious diseases deserve special attention: the 
metabolome of an infected organism, in fact, represents not only the metabolic phenotype 
of the host and/or the pathogen but it also depicts their cross-talk. Furthermore, for a 
comprehensive view of the metabolic pattern, multiple factors have to be taken into account 
such as the risk of exposure and the host’s individual susceptibility to a given infection. 
Moreover, the word ‘pathogen’ encompasses a variety of infectious agents with very diverse 
invasion properties which are able to activate different pathways of the host immune system. 
The bulk of the literature dedicated to the metabolomics of infectious diseases concerns 
animal studies. For example, explorative studies of parasitic infections have been dedicated 
to the understanding of the pathogen metabolism and/or the host response after inducing 
the infection. Explicative examples are the most widespread parasite infections, namely 
malaria and schistosomiasis. For malaria, it has been shown that the dominant change in the 
urinary metabolic profile may provide a sensitive diagnostic tool for Plasmodium infection 
and for the evaluation of the malaria progression in mice [9]. A particular relevant finding is 
the specific conversion of arginine to ornithine induced by the parasite [10]. Tissue material 
has also provided interesting data for the understanding of the metabolic pathways. In 
fact, most tissues obtained from S. mansoni-infected mice were characterized by high levels 
of amino acids (leucine, isoleucine, lysine, glutamine and asparagine) and high levels of 
membrane phospholipid metabolites (glycerophosphoryl choline and phosphoryl choline). 
Additionally, low levels of energy-related metabolites (lipids, glucose and glycogen) were 
observed in ileum, spleen and liver samples of infected mice. These findings show that a S. 
mansoni infection causes a clear disruption of the metabolism in some tissues, which are in 
accordance with the previously reported indications in a biofluid (urine) [11].
METABOLOMICS OF THE URINARY TRACT INFECTION (UTI)
Despite the encouraging results achieved in animal model and in vitro studies, real 
clinical metabolomics studies in the field of infectious diseases are still lacking. Although 
large population studies are nowadays a matter of fact, the step from an ideal and controlled 
situation represented by a ‘synthetic’ study to human situation still appears tedious. In this 
respect, urinary tract infection (UTI) represents a real life situation in a clinical context and 
the comprehensive study of the UTI-induced changes in the metabolic pattern may offer the 
possibility to extensively investigate such a complex infection in man. This clinically well-
defined disease represents a good model for the development of an analytically based scoring 
system of disease severity or/and evaluation of the effectiveness of a treatment. Urinary tract 
infection (UTI) is an inflammatory response to the presence of single or multiple species 
of pathogens in the urinary tract, with a high incidence of Escherichia coli, Pseudonomas 








Despite the efficacy of the medical care and antibiotic treatment, UTI still contributes 
significantly to the annual morbidity and mortality rate in Western countries.
In a first approximation, UTI can be grouped into acute uncomplicated UTI (non-
pregnant young women with cystitis but no evidence of urological abnormalities) and 
complicated UTI (UTI in males, all febrile UTI syndromes and those with urological 
abnormalities). In this respect, fever reflects the presence of a tissue invasive disease such as 
pyelonephritis, prostatitis or the urosepsis syndrome. The clinical management of UTI is 
relatively straightforward, but obtaining guidance for the duration of the treatment or for 
scaling of the morbidity inflicted to, for example, prostate or kidney is not such a simple 
task. 
The identity of the causal pathogen is confirmed by a urine culture test. This typically 
needs 24-48 hours before the results are available. An alternative diagnostic method routinely 
used in clinical laboratories is a nitrite dipstick test: a fast and cheap method but with a 
high incidence of false-negative results, especially in the case of a Gram-positive bacteria 
pathogen.
An early and accurate diagnostic method would be valuable for a correct and prompt 
medical treatment, especially in view of the fact that epidemiological data suggest that a 
poorly diagnosed UTI or a recurrent UTI due to antibiotic-resistant pathogens is associated 
with a higher mortality rate [12, 13]. To this end, the scientific literature presents a growing 
range of NMR- and MS-based methods for fast identification of the pathogen [14]. It has 
been shown that uropathogens present a specific metabolite pattern which under controlled 
conditions can be used for accurate identification within six hours. For instance, in vitro 
studies have revealed specific metabolic ‘signatures’ for the different uropathogens: E. coli 
produces lactose from the lactate metabolism, K. pneumoniae produces 1,3 propanediol 
from the glycerol metabolism, P. aeruginosa produces 6-hydroxy nicotinic acid from the 
nicotinic acid metabolism and P. mirabilis produces 4-methylthio-2- oxobutyric acid from 
the methionine metabolism.
It has become evident that a molecule-based approach has practical value for the 
development of novel diagnostic tools. Furthermore, metabolomics creates new possibilities 
for the investigation of the host-pathogen cross-talk. This new aspect might help in more 
accurately scaling the progression of morbidity, a subject which has been largely ignored till 
this moment, and can help in the evaluation of the risk of the recurrent UTI. In fact, from a 
clinical point of view, recurrent and complicated UTI are more challenging problems since 
they can lead to more serious and life-threatening problems till organ failures.
The modeling of the metabolic phenotype has matured and improved over the years 
and is, nowadays, influencing translational medicine through the screening of a large cohorts 
of individuals with the ambition to deliver a classification in many different scenarios. An 
obvious application is the investigation of metabolic diseases often caused by a dysregulation 
in the metabolism of small molecules. It has been shown how a multiplatform approach to 
the metabolome-wide analyses of diabetes leads to a more sophisticated classification of the 
disease and the evaluation of the disease progression. Key observations could be linked to 
a series of metabolic plasma perturbations linked to kidney dysfunctions, lipid metabolism 
and gut microflora [15]. One of the first examples of a metabolome-wide association study 
has analysed risk factors (diet and blood pressure) in relation to exploratory spectroscopic 
data allowing the identification of good candidates for the metabolic signature of disease risk 
in different populations [16].
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On the basis of the findings for metabolic diseases, a multiplatform explorative study 
could be expected to reveal the uropathogen expression and, even further, might uncover 
the response of the host and the complex signaling between the host and the (uro)pathogen. 
The so defined molecular pattern might lead to a deeper knowledge of the metabolome of 
UTI patients and thus to a more accurate disease classification and better understanding of 
the severity of the morbidity.
ANALYTICAL TECHNOLOGIES IN METABOLOMICS
The last decades of 20th century are often called the ‘years of biology’, a time when 
biomedical sciences made an enormous progress. Analytical and technical solutions, enabling 
large scale analysis of the ‘biopolymers’ (DNA, RNA and proteins), have played an important 
part in this phenomenon. The term ‘biopolymer’ implies the biological origin of a molecule 
and the limited number of monomeric units it consists of. A restricted number of the building 
blocks confines the chemical diversity of the oligomers (the analysis of which constitutes the 
basis of the analytical workflows) and at the same time one of the major analytical challenge, 
for example, in protein analysis remains the dynamic range. For metabolomics, dynamic 
range is just one of the challenges. The diversity of the physico-chemical properties of the 
metabolites is another one. Indeed, unlike the terms polynucleotides and polypeptides, 
the term ‘metabolites’ does not refer to a particular chemical family; even more, the most 
logical definition of metabolites is not a chemical but a functional one – the end products 
and intermediates of metabolism. Thus, metabolites belong to different chemical families 
and have a diverse size and polarity; their ‘apparent simplicity’ hides a concrete obstacle 
for the standardization of the analysis methods. Moreover, none of the existing analytical 
techniques provides a coverage of the entire metabolic space and therefore the analysis of the 
metabolome demands a multiplatform approach.
For metabolite profiling purposes, Nuclear Magnetic Resonance spectroscopy (NMR) 
and Mass Spectrometry (MS) are the main techniques applied.
Since the early 80’s, NMR has been the first choice in metabolomics studies aiming at 
the analysis of body fluids [17, 18]. NMR is a highly robust and reproducible technology 
based on the detection of the resonance frequency of the atoms’ nuclei when these are 
exposed to a magnetic field. Due to the high abundance of the 1H nucleus, 1H-NMR has 
been widely employed for metabolome profiling: any hydrogen-containing molecule in 
body fluids and tissues is potentially detectable. NMR is a non-destructive technique, can 
be largely automated and requires minimal sample preparation, all perfect characteristics 
for implementation in large scale clinical studies. In addition, according to its detection 
modality high-resolution NMR offers simultaneously structural elucidation and absolute 
quantification (at sub-micromolar range).
Despite the incomparable high throughput and the power of structural analysis, NMR 
only (un)covers a fraction of the metabolome, and thus mass spectrometry which may 
involve multiple ionization techniques, mass analyzers and hyphenation solutions represents 
a strong complementary technology. In mass spectrometry, molecules are detected on the 
basis of their mass over charge ratio (m/z) after an ionization process. Over the last decade, 
MS has become one of the key analytical methods in the biomedical sciences, primarily 
due to its potential to measure hundreds of metabolites over a wide dynamic range with 








destructive technique, the metabolite profile is more susceptible to variability and results are 
platform-dependent. Recent improvements in achievable mass resolution and mass accuracy 
have enormously facilitated the task of structural elucidation of metabolites, with a mass 
accuracy often lower than a few ppm.
MS techniques show their best potential when used in the classical set-up of hyphenation 
with a separation technique which brings both benefits and complications. An MS analysis 
is more time consuming than NMR because of a number of reasons, such as the need of a 
more extensive sample preparation, a longer analysis-time and a more difficult interpretation 
of the resultant spectra. However, the hyphenation also provides extra information on the 
compounds’ polarity, size or charge and reduces the complexity of the metabolic profile. 
The most commonly used separation techniques in combination with MS encountered in 
literature are liquid chromatography (LC-MS), gas chromatography (GC-MS) and capillary 
electrophoresis (CE-MS).
Of these, probably, the most applied hyphenation for profiling purposes is LC-MS 
due to its high versatility and the capability to analyze a wide variety of compounds. In 
addition there is a number of different columns, organic modifiers and technical solutions in 
order to maximize the chromatographic separation and MS ionization/detection with regard 
to a single compound, a certain matrix, or a specific compound family. For instance, the 
‘straight forward approach’ encompasses the use of reversed phase columns that poorly retain 
polar compounds; to overcome this issue, hydrophilic interaction chromatography offers a 
solution. The advent of ultra high pressure LC systems (UPLC) in combination with MS 
analyzers has dramatically improved the chromatographic resolution, the peak capacity, and 
has reduced the limits of detection down to the picograms level while it also allows a better 
high-throughput capability than classic HPLC systems. Moreover, this type of platform 
allows coverage of a greater number of polar metabolites which increases its applicability 
and makes LC-MS an even more powerful technique for biomolecular research. Apart from 
improvement at the LC level, electrospray ionization (ESI) has significantly contributed to 
the success of LC-MS in its role of the perfect hyphenated technique for the analysis of the 
body fluids. For example, urine can be directly injected into LC-MS system and a plasma 
sample can be analyzed after minimal sample processing (protein precipitation).
GC is one of the oldest separation techniques and the first of the three separation 
techniques mentioned above which was used in a metabolite profiling study [19]. Despite 
its ‘age’, it still remains the only chromatographic technique able to separate, with high 
reproducibility, hundreds of compounds in one single run. GC-MS allows the simultaneous 
detection of a wide variety of analytes, although a derivatization step is often required which 
may be time-consuming and costly. The traditional sources for GC-MS are equipped with 
a vacuum stage interface – namely electronical impact (EI) and chemical ionization (CI). 
Under these conditions, EI fragmentation patterns have shown to be reproducible and as 
a result a number of open source and commercial spectral libraries are available which can 
be used for structural assignment. Nevertheless, the occurrence of extensive fragmentation 
can make the identification of unknown compounds in complex samples a challenging 
task. CI provides a softer ionization but the resultant spectra are strongly dependent on 
the experimental conditions (gas reagent, gas pressure) which makes the data less suitable 
for library search. The structural assignment of the compounds is, by its nature, the slowest 
element in an exploratory ‘omics’ workflow and there is always a place for new technology. 
Atmospheric Pressure Chemical Ionization (APCI) appears as a natural choice for a GC 
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platform. GC-APCI has recently been reintroduced for profiling aims after decades of 
oblivion. Reviving this technique has required a general optimization and definition of the 
analytical parameters as is shown in chapter 4 of this thesis. Moreover, one of the factors 
which seriously prevents GC-APCI from becoming a routine platform for explorative 
studies is the lack of a spectral such as extensively available for the more traditional sources. 
The first public spectra library for the APCI source is now available (http://metams.lumc.nl) 
(chapter 5) including a wide number of compounds (primary and secondary metabolites) 
most commonly encountered in the analysis of body fluids.
As indicated above, any single analytical detection modality brings its specific pros and 
cons, and thus the use of a multiplatform strategy to undertake an explorative metabolomics 
study of a clinical disease seems the most logical approach. UTI is almost an ideal test to 
prove how a metabolomics approach can offer a more comprehensive understanding of this 
complex clinical entity. The various analytical techniques have each worked as a magnifying 
lens providing a view on the metabolic signature and allowing a different perspective on 
the same pathological problem. The measurement of different panels of metabolites is the 
consequence of the complex status of the infection which represents a complex system where 
the host and the invader ‘fight’ their battle releasing specific chemical signals which may or 
may not be detected.
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Metabolomics has a special place among other ‘omics’ disciplines (genomics, 
transcriptomics and proteomics) as it describes the most dynamic level of biological 
regulation and, as such, provides the most direct reflection of a physiological status of an 
organism. Quick development of the analytical technologies in the first place –MS and 
NMR– has enabled the metabolomics analysis of such complex biological phenomena as 
host-pathogen interactions in the development of infection. In this review, an overview of the 
metabolomics studies of the infectious diseases carried out on human material is provided. 
The relevant papers on the metabolomics of human infectious diseases are comprehensively 
summarized in a table, including, for example, information on the study design, number of 
subjects, employed technology and metabolic discriminator. Future considerations, such as 
importance of the time-resolved study designs and the embedment of metabolomics in the 





Recent advances in technology have strongly stimulated the development of the 
exploratory study models known otherwise as ‘omics’, for example, genomics, proteomics 
and metabolomics. The latter one refers to a study of the metabolome –the ‘complete’ set of 
the metabolites (small-molecules such as metabolic intermediates, amino acids or hormones) 
to be found within a biological sample [1, 2]. As the metabolome provides the most direct 
reflection of a physiological status or an organism, metabolomics is increasingly integrated in 
clinical studies as an essential phenotypic measure. A good overview of the technological basis 
and current achievements of metabolomics can be found in a number of excellent reviews 
that have been published over the last decade [3, 4]. Here, however, we will concentrate only 
on the progress in the field of metabolomics related to studies on of infectious diseases. 
There are several reasons why metabolomics of infectious diseases requires special 
attention. First, every infectious disease is a process of host-pathogen interaction; thus with 
regard to metabolomics, the metabolic signature of an infected host represents the reciprocal 
actions of the host and the pathogen or their metabolic cross-talk [5]. Second, although 
the risk of exposure to a pathogen and the environment of a host play the most important 
part, genetic susceptibility of the host to an infection and consequently the host’s metabolic 
individuality should not be underestimated. Finally the enormous diversity of pathogens 
should be mentioned. The evolutionary distance between pathogens is considerable; their 
‘strategies’ for invasion of the host and evasion of the host’s immune system differ extremely, 
which makes any straightforward generalization questionable.
Such a diversity complicates a review as well, since our perception of the progress in the 
field will be affected by the perspective taken. One could, for example, build an overview 
grouping the available material as traditional, emerging or re-emerging infections, or use a 
biological classification of the pathogens: bacterial pathogens, viruses, protozoa, helminths. 
Alternatively, one could consider a problem from the perspective of the type of the infection - 
acute or chronic. Assuming that the ‘metabolic costs’ and mechanisms mobilized by the host 
during the acute response are different from those used in the chronic phase, an overview 
of the metabolomics of human infections from a such point of view appears to be the most 
logical one.
METABOLOMICS OF THE INFECTIONS IN THE ACUTE PHASE
Every pathogen has to survive the acute-phase response of the host, but the development 
of the acute phase into a life-threatening condition happens not so often. Many pathogens 
are capable of subverting the initial reaction of the host and progress to a chronic phase. 
Consequently, here we try to address only those acute infections that are known as distinct 
clinical entities, such as, for example, urinary tract infection (UTI), which is indeed the most 
common bacterial infection leading to considerable health care expenditures. In fact the 
term ‘urinary tract infection’ encompasses a variety of clinical syndromes with the common 
denominator of a positive urine culture (i.e., significant bacteriuria > 103 CFU/ml) [6]. 
However, the presence of bacteria in urine is essential but not sufficient for the diagnosis 
of UTI and the correct assessment of the disease relies on a coordinated effort of clinicians 
and microbiologists. Within the limited number of metabolomics studies that have been 
performed on clinical material, UTI appears to be the most common topic. 







be applied, play an important role in those studies, regardless of whether an exotic technology 
is introduced [7] or a standard metabolomics technology, for example LC-MS, is used. A 
recent study of Lv et al. represents a good example of this technology-driven approach. The 
study is dedicated to the development of an LC-MS based method for metabolic profiling 
of UTI samples [8]: it includes optimization of the protocol, testing of columns with 
different particle sizes and both positive and negative ionization modes. The technology 
validation was followed by the analysis of a limited selection of samples. The authors thus 
identified a number of metabolites being specific for UTI (Table 1). However, it might be 
argued that far reaching biological conclusions, based on analysis of only a few samples, 
may need a critical re-evaluation. The work of Pacchiarotta et al. is another example of the 
use of the LC-MS technology for studying metabolomics of UTI [9]. Taking advantage of 
a prospective observational multicenter cohort study, the authors have selected a group of 
patients with culture-confirmed febrile Escherichia coli UTI. The study design included the 
control samples and samples of UTI patients collected at baseline (t=0) as well as patient 
samples collected after the antibiotic treatment (t=30). Thus, the authors had the possibility 
to not only compare UTI patients with symptom-free controls but also to observe how the 
metabolic phenotype of the patients reverts after the treatment. In doing so, they identified 
unique O-glycosylated fragments of the human fibrinogen alpha 1-chain and showed that 
presence of those fragments in urine strongly correlated with UTI symptoms.
Slupsky et al. explored another clinically important infection, namely acute 
pneumococcal pneumonia [10]. Pneumonia, like UTI, is a complex clinical entity, where an 
infection of the lower respiratory tract caused by bacteria or viruses is the common feature. 
The pneumococcal pneumonia caused by Streptococcus pneumonia is the main community-
acquired form of the disease. To dissect the metabolic signature (‘metabotype’ according 
to authors’ terminology) specific for S. pneumonia infection, a combination of targeted 
quantitative NMR profiling (61 metabolites) and a rather sophisticated study design was 
used. Anticipating that an acute infection represents a situation of metabolic stress for the 
host, the authors took a number of steps to ensure the specificity of their findings: the 
selection of patients included several additional ‘control’ groups of patients such as patients 
with non-infectious metabolic stress (cardio-vascular failure), patients with lung infections 
caused by other pathogens, fasting individuals and so on. Furthermore, a small longitudinal 
study on a sub-selection of eight samples was undertaken to monitor the evolution the 
‘metabotypes’ of the patients. The approach used by the authors in the study design should 
serve as an example for future studies on metabolomics of infectious diseases. Still, one 
might ask whether an exploratory analysis of the entire NMR spectra could reveal more 
interesting compounds than those which were included in the list. 
There are number of clinically relevant pathogens which present a threat to the human 
host during the acute phase of the infection. At first glance, it appears that many of those 
have been well studied and some (e.g., Salmonella sp.) have even been ‘developed’ into the 
standard model systems. However, the bulk of the publications address the metabolism of 
the pathogens in vitro or in animal models and the real clinical metabolomics studies of such 
important pathogens as Vibrio cholerae or even the otherwise well studied Salmonella are still 
awaiting their time. 
Acute viral infections, such as influenza, represent a serious threat to the global health 
system. The previous pandemics (1918, 1957 and 1968) have clearly demonstrated the scope 




and the effect of antigenic drift –a gradual change of the viral antigenic pattern due to 
frequent mutations [12]. Thus, even if a human host will acquire immunity to the invading 
strain, every new strain, originated as a result of the antigenic drift, can evade the host 
immune system. The value of the metabolomics studies in global control and management 
of influenza is far from being self-evident, which probably explains the lack of such reports 
in literature. There are, however, some publications addressing the impact of the virus on the 
metabolism of the hosts’ cells. For example, Lin et al. have explored the metabolic pattern 
of human cell lines infected with influenza A virus [13]. They indicated that the metabolic 
signature might be associated with differentiated stages of the cells, probably due to fatty 
acids and cholesterol biosynthesis. Another possible niche for metabolomics study in a 
context of influenza infection could be an exploration of the ‘collateral damage’ effects like 
influenza-associated encephalopathy characterized by abrupt onsets of unconsciousness. The 
last case was addressed by Kavashima et al. who have studied CSF samples from six children 
affected by influenza-associated encephalopathy [14]. Using a high-field mass spectrometry 
(7 Tesla APEX III FTMS, Bruker Daltonics) authors have identified a number of signals 
specific for influenza-associated encephalopathy. However, neither statistical validation of 
the results, nor structural assignment of the signals, was presented. 
METABOLOMICS OF THE INFECTIONS IN THE CHRONIC 
PHASE
If the question ‘what do viruses and helminths have in common?’ will ever be asked, 
a possible answer could be that these groups of organisms are ‘masters of subversion’. To 
formulate it in more formal language, many viruses and helminths have the exceptional 
ability to develop long-lasting infections and coexist with the host for years or even decades. 
Hepatitis C virus (HCV) is a good example: in early infection the virus presents little to 
no damage to the host, however in the chronic infection it leads to progressive loss of liver 
function in 70% of patients [15]. Liver biopsy is still considered an essential element of 
HCV management and, thus, it comes as no surprise that one of the first applications of a 
metabolomics approach to this infection was an attempt to find an alternative way for the 
estimation of HCV-related morbidity. Zhang et al. have used targeted profiling of amino 
acids to reassess an old association between liver fibrosis and Fisher’s ratio: the molar ratio 
of branched amino acids to aromatic ones. [16, 17]. A chronic Hepatitis B infection also 
results in the losses of liver function and an increase in the risk of hepatocellular carcinoma. 
A strong correlation between this morbidity and the levels of free amino acids in serum of 
HVB infected patients has been shown by Yu et al. [18].
An overview of the work carried out on HIV would require a separate review. There 
is a large body of literature dedicated to the studies of antiviral drugs and the metabolism 
of human CD4+ T-cells infected with the virus. Furthermore, an in-depth analysis 
of the metabolomics of HIV should discuss a fraction of the literature dedicated to the 
fundamentals of the human metabolism in the context of HIV infection and effects of the 
nutritional status of the host. These studies seldom use the ‘metabolomics rhetoric’ but they 
are essential for understanding the long-term effects of the infection. ‘Classical’ large-scale 
metabolomics studies on HIV are still lacking. However an original approach to the problem 
was taken by Ghannoum et al. who have evaluated oral wash samples as potential material 







LC- and GC-MS, the authors have generated an overview of the metabolic composition of 
the oral cavity. The identity of all discussed metabolites has been verified by a custom built 
library of analytical standards. Next to the comparison between a control group and HIV 
patients a table summarizing the metabolic differences amongst HIV patients (naïve and 
exposed to the antiretroviral therapy) was presented. However, a closer examination of the 
reported p-values shows that the differences within the HIV group (naïve vs. antiretroviral 
therapy patients) are apparently more significant than between HIV and control groups. An 
interesting fact, which unfortunately was not discussed by the authors. While the biological 
system assumptions of the authors might need an independent validation on a larger set 
of samples, the idea to use the metabolome of the oral cavity for monitoring of the status 
of a viral infection opens many interesting possibilities. Oral wash has indeed a number of 
advantages: it is safer to handle than blood, it allows noninvasive sampling, the volume of 
the sample can be controlled and finally it is always available, which makes it an almost ideal 
sample for the ‘time-resolved’ studies [19].
A long-lasting coexistence with the host is typical for the survival of many parasitic 
helminths species. Some of these helminths, for example trematodes of the genus Schistosoma, 
can survive for decades. Schistosomiasis is after malaria the second most socio-economically 
devastating parasitic infection. According to the World Health Organization (WHO) there 
are approximately 200 million people chronically infected and 600 million at risk of the 
infection (www.who.int). Unlike malaria, where a large-scale clinical metabolomics study 
is still lacking, schistosomiasis has already attracted the attention of the metabolomics 
community. Two large NMR studies have been published within 4 years [20, 21]. Both 
studies were based on material collected in endemic areas: Ivory Coast [20] and in Uganda 
[21]. Despite many factors (geographical location, nutritional habits, co-infections) that 
make a direct comparison of the two studies difficult, both groups have reported that the 
age of the participants is a dominant source of the variance the data overshadowing all other 
factors including infection status and parasitic load. Anticipating this effect, Balog et al. have 
analysed their cohort by splitting it in two age-matched sub-groups; the first one included 
participants of 7-15 years old and the second of 20-40 years old. The list of the metabolic 
discriminators presented by the authors includes no surprising entries, but the data overlap 
significantly with results obtained on animal models [20, 22].
It is evident that viruses and helminths are not the only organisms causing chronic 
infections; bacterial pathogens, such as mycobacteria, can also be very efficient in subversion 
of the host defence and in long-time survival. The best example is Mycobacterium tuberculosis 
- the causative agent of the one of the most widespread of all human infectious diseases - 
tuberculosis (TB). The impact of the TB on the human population is so profound that the 
WHO has declared the state of a Global Emergency in 1993. With the development of 
multi-drug resistant tuberculosis, the decision of the WHO can hardly be considered as an 
overreaction. The value of the metabolomics for a systemic approach to the TB problem 
has been recognised already for some time and has even been addressed in several reviews 
[23, 24]. However, no metabolomics study on human material has been published so far 
and a study on a mouse model remains our closest approximation [25]. Leprosy, caused by 
Mycobacterium leprae, is another important mycobacterial infection. In comparison to TB, 
leprosy might appear to be a relatively minor problem but more than 200000 new cases 
worldwide were reported in 2010 alone [26] and this disease still represents a peculiar case 




work by Al-Moubarak et al. on metabolomics of Mycobacterium leprae [28] is to the best of 
our knowledge the only metabolomics study of a Mycobacterium infection performed on 
human material. The authors employed UPLC-MS for their study and used serum samples 
from a sample bank of an on-going project on the molecular epidemiology of leprosy. This 
technologically solid study has nevertheless one small weakness with respect to the sample 
selection. By comparing patients with high and low bacterial indices (BI), and by using a 
random sample selection from the database they ended up with two very unbalanced groups. 
The group of high BI consisted of only males (only one female) while the same time group of 
low BI was mixed. Thus, it remains an open question to what extent the differences reported 
by the authors can be attributed to the differences in the infectious status.
FUTURE PERSPECTIVES
The current overview covers only a fraction of the literature on the metabolomics of 
infectious diseases, namely studies performed on human material. At a first glance, the 
progress in this field might appear insignificant in comparison to such areas as metabolic 
syndrome, cardiovascular disorders or cancer [29-31]; only a limited number of studies 
have appeared and the data on some common infectious diseases, such as TB or malaria 
remain unavailable. Furthermore, the sets of specific metabolites observed often consist of 
a selection of the usual suspects (carboxylic acids, amino acids, sugars; for more details see 
Table 1) leading to the quite common conclusion about the involvement of the energy 
metabolism in the host reaction to an infection.
On the other hand, the link between the regulation of the host energy metabolism and 
the response to an infection has been known for decades and one might argue that the ability 
of a new technology to expose this well-established physiological phenomenon should be 
considered as a positive fact which provides a solid foundation for future investigations [32-
34]. With regard to the usual suspects, one could emphasize the fact that, in general, not one 
or two specific metabolites but a specific panel of metabolites or even the metabolic pattern/
profile of an organism as a whole should serve as a basis for clinically relevant conclusions. 
However, to identify those metabolic patterns, to reveal their specificity and to show their 
feasibility for clinical research, the static case-control study design will have to be substituted 
by a longitudinal one or any other type of design where time-dependent phenomena can 
be explored. So far, only a few studies (Slupsky et al. [10], Pacchiarotta et al. [9] –bacterial 
pathogens– and Balog et al. [21] –parasitic infection) have employed such designs.
Although, metabolomics of the infectious diseases is still in its early days, we are 
confident in its future. In a way, it is, probably, the most systemic part of the systems biology: 
it studies a unique phenomenon of the interaction of a pathogenic organism with human 
super-organism [35]. At the moment, it is difficult to foresee the way this field will evolve. 
Yet we might speculate that in the case of acute infections, a practical approach will not 
be the development of the diagnostics, which is usually established in clinical laboratories, 
but, for instance, the development of the analytically based scoring systems for the scaling 
of morbidity, or estimation of the response to treatment. The latter aspect is becoming 
increasingly important as the list of antibiotic-resistant strains is becoming longer and 
longer. With regard to chronic infections, an exploration of the metabolic trajectories of the 
infections unfolding in time is probably the most logical way to achieve the practical results. 







in the large-scale epidemiological projects as a standard phenotypic measure.
Table 1. Overview of the works available on human material divided by acute and chronic 
infections.










TCA cycle intermediates, branched amino 
acids, creatinine, taurine, myo-inositol 641 1, 2 2009 [10]
E. Coli Urine CE-MS Phenylalanine, glutamic acid 18 1 2008 [7]
E. Coli, Gram 
positive Urine UFLC-MS
TCA cycle, terpenoid backbone biosynthesis,  
amino sugars and nucleotide sugars 
metabolism,  arachidonic acid and steroid 
hormone biosynthesis
17 1 2011 [8]




media NMR Glycerol metabolism 614 1 2006 [36]






Lactate metabolism, methionine metabolism, 
nicotinic acid 617 1 2009 [37]




Urine SELDI-ToF, NMR N/A 80 1 2003 [38]
Plasmodium 
falciparum Urine NMR Lipids, lactate 39 1 1988 [39]
Plasmodium 
falciparum Red blood cells NMR
Gamma aminobutyric acid (GABA), TCA 
intermediates, glutathione 2009 [40]
Influenza virus CSF Direct Infusion MS N/A 6 1 2006 [14]
Hepatitis C virus Urine NMR N/A 66 1 2010 [41]
Hepatitis C virus Plasma HPLC-MS Branched and Aromatic Amino acids 53 1 2006 [17]
Hepatitis B virus Serum GC-MS Branched and Aromatic Amino acids 47 1 2006 [18]
Hepatitis B virus Plasma GC/MS
Acetic acid, sorbitol, D-lactic acid, hexanoic 
acid, 1-nephtalenamine, butanoic acid, 
phosphoric acid, D-glucitol, glucose
40 1 2009 [42]
Hepatitis B virus Serum LC-MS Lysophosphatidyl cholines, bile acids, hypoxanthine stearamide 59 1 2011 [43]
Hepatitis B virus Plasma UPLC-MS Lysophosphatidyl cholines, primary fatty acid amides, comjugate bile acids 83 1, 2 2011 [44]
HIV virus Oral wash samples GC-MS, LC MS
Phenylalanine:tyrosine metabolism, 
aminosugars metabolism, purine metabolism, 
fructose mannose galactose, starch and 
sucrose metabolism, TCA cycle
24 1 2011 [19]
HIV virus Plasma HPLC-fluorescence Phenylalanine/Tyrosine 107 2 2010 [45]
HIV virus Plasma NMR Lipids, Glucose 63 1 2006 [46]
Mycobacterium 
Leprae Serum UPLC-MS Polyunsaturated Fatty Acids, phospholipidis 23 1 2011 [28]
Schistosoma 
mansoni Urine NMR TCA cycle, liver function, gut microflora 447 1, 2 2011 [21]
Schistoma 
mansoni Urine NMR N/A 1 2007 [20]
Onchocerciasis 
volvulus
Serum LC-MS Fatty acids, sterol lipids 73 1 2010 [47]
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Urinary tract infection (UTI) encompasses a variety of clinical syndromes ranging 
from mild to life-threatening conditions. As such, it represents an interesting model for 
the development of an analytically based scoring system of disease severity and/or host 
response. Here we test the feasibility of this concept using 1H NMR based metabolomics 
as the analytical platform. Using an exhaustively clinically characterized cohort and taking 
advantage of the multi-level study design, which opens possibilities for case–control and 
longitudinal modeling, we were able to identify molecular discriminators that characterize 
UTI patients. Among those discriminators a number of compounds  (e.g. acetate, 
trimethylamine and others) showed association with the degree of bacterial contamination 
of urine, whereas others, such as, for instance, scyllo-inositol and para-aminohippuric acid, 





Despite the progress made in understanding the mechanistic basis of many diseases 
in the last century, medicine is still essentially ‘more an art than a science’ [1]. Discovery of 
biochemical markers is thought to improve this, making diagnosis more reliable, specific 
and sensitive. These markers are sought at different levels of biological processes with the 
help of genomics, transcriptomics, metabolomics and other ‘omics’ approaches. Of these, 
metabolomics focuses on the analysis of metabolites present in biological fluids. Metabolites 
are end-points of all the biochemical processes of the organism and thus their collection – 
the metabolome is the closest approximation of the physiological phenotype and as such 
has a great potential for uncovering the biology underlying diseases and providing valuable 
markers of pathology [2,3]. 
The biological interpretation of results from metabolomics studies is rather complex and 
still in an early phase of development [4]. The human body is a ‘super-organism’ that unites its 
own network of interconnected tissues and organs with multiple colonies of microorganisms 
[5]. Interpretation of changes in concentration of metabolites found in biological fluids can 
readily be performed based on the underlying metabolic pathway; however, it is not always 
possible to link the observed change in systemic metabolite concentrations to a specific tissue 
or organ [6]. Especially in the case of disruption of highly abundant metabolites, e.g. from 
energy or amino acid metabolism, additional information would be required in order to 
interpret the data in respect to the tissue of origin. In addition, a change of such metabolites 
does not always improve the knowledge about the underlying cellular mechanisms and 
biology. A way to facilitate the interpretation of clinical metabolomics data is to integrate a 
plethora of available clinical parameters and to utilize a multilevel study design that should 
provide the opportunity to access the various levels of biological processes.
One of the examples of a complex and heterogeneous clinical entity, for which current 
diagnostic methods are not straightforward, is Urinary Tract Infection (UTI) [7]. Clinical 
manifestation of UTI can cover the range from mild cystitis to advanced pyelonephritis 
potentially leading to urosepsis and kidney failure. Physical symptoms may vary from patient 
to patient and be similar to a number of other diseases, mainly of infectious origin.  Thus, 
the presence of bacteria and lymphocytes in urine can not be considered as a sole common 
denominator for UTI and even if it was, the criterion for the colony count is variable and 
anyway considered insensitive [8]. The correct and timely diagnosis relies on effective joint 
work of clinicians and microbiologists [8]. All of this explains the considerable interest 
in providing new, specific and sensitive markers for UTI, as well as for the uropathogen 
involved. The focus of the available metabolomics studies on UTI in the literature has so 
far been on the identification of pathogens: in the work of Gupta et al. a beautiful method 
with the use of 1H NMR was proposed [9–11]. However, regrettably the method is not 
quantitative nor does it provide any information about the localization of the infection 
within the urinary tract, morbidity and preferred strategy of treatment 
In the current study we investigated possibilities of using urinary metabolic profiles to 
monitor the health state of UTI patients, the degree of infection and the recovery process of 
UTI patients in the context of febrile, complicated UTI. We used a selection of samples from 
an exhaustively characterized cohort, with multiple urine samples available per individual 
and with the main pathogen identified as Escherichia coli, which is the most common 
pathogen for UTI. Samples from a group of age- and gender- matched UTI symptom-







biological processes: not only the difference between the patients and controls, but also the 
recovery process, using each patient as its own control.
MATERIALS AND METHODS
Samples
The study protocol was approved by the ethical committee of the Leiden University 
Medical Center and all included patients gave written informed consent.
Urine samples were collected at the Emergency Department and Primary Care 
Department. The sampling was carried out at several time points: the first urine samples were 
collected at the day of enrolment as baseline samples (t=0). Clean midstream-catch urine 
cultures were obtained and were analyzed using local standard microbiological methods. 
Three-four (t=4) and thirty days (t=30) after the day of enrolment, urine samples of the 
same patients were collected and new bacterial culture tests were performed (Supplementary 
Figure 1). 
For the current study, from a database of about 700 subjects enrolled, 40 subjects, for 
which urine culture confirmed E.coli-positive complicated febrile urinary tract infection that 
recovered after antibiotic treatment, were selected. Samples from age- and gender- matched 
subjects with low bacterial culture in urine and without evidence of inflammatory diseases 
were used as controls (Table 1). A number of samples were missing, a few removed from the 
analysis due to either insufficient spectra quality or high glucose content (Supplementary 
Figure 1). In the end the study included four classes of samples originating from UTI 
symptom-free (N = 35) at day 0 (baseline control), UTI patients (N = 32) at day 0 (baseline), 
UTI patients (N= 29) at day 4 and UTI patients after recovery from infection (N = 37) at 
day 30 (Supplementary Figure 1).
Table 1. Characteristics of the studied patients and controls groups at baseline (t=0).
Characteristics UTI patientsn = 40
Controls
n = 40 p
Age, years,  median (sd) 59 (14.6) 58 (17.9) 0.9
Female, n (%) 22 (55) 22 (55) 1
Smoking, n (%) 5 (12) 5 (12) 1
Co-morbidity, n (%)
Urinary tract disorder 4 (10) 4 (10) 1
Malignancy 4 (10) 1 (3) 0.17
Heart failure 5 (13) 3 (8) 0.46
Renal insufficiency 1 (4) 0 (0) 0.13
Diabetes mellitus 6 (15) 2 (5) 0.14
Immunocompromised 1 (3) 1 (3) 1
Urine dipstick results
Nitrate 26/37 (75)* 0/37 (0)* < 0.001
Leucocyte esterase 35/37 (95)* 5/37 (14)* < 0.001





Samples were thawed, transferred into 96 deep-well plates and centrifuged at 3000g 
for 15 minutes at 4°C to remove any precipitate. For sample preparation 520 µL urine were 
mixed with 60 µL of pH 7.0 phosphate buffer (1.5 M) in 100% D2O containing 4 mM 
sodium 3-trimethylsilyl-tetradeuteriopropionate (TSP) and 2mM NaN3 in a 96 deep-well 
plate using a Gilson 215 liquid handler controlled by a Bruker Sample Track LIMS system 
(Bruker BioSpin, Karlsruhe, Germany).
NMR experiments and processing
1H NMR data were collected using a Bruker 600 MHz AVANCE II spectrometer 
equipped with a 5 mm TCI cryogenic probehead and a z-gradient system; a Bruker BEST 
(Bruker Efficient Sample Transfer) system was used in combination with a 120 µL CryoFIT™ 
flow insert for sample transfer. One-dimensional (1D) 1H NMR spectra were recorded 
at 300 K using the first increment of a NOESY pulse sequence [12] with presaturation 
(γB1=50 Hz) during a relaxation delay of 4 s and a mixing time of 10 ms for efficient water 
suppression [13]. Eight scans of 65,536 points covering 12,335 Hz were recorded and zero 
filled to 65,536 complex points prior to Fourier transformation, an exponential window 
function was applied with a line-broadening factor of 1.0 Hz. The spectra were manually 
phase and baseline corrected and automatically referenced to the internal standard (TSP 
= 0.0 ppm). Phase offset artifacts of the residual water resonance were manually corrected 
using a polynomial of degree 5 least square fit filtering of the free induction decay (FID) 
[14]. In order to monitor proper filling of the NMR flow cell and for quality control 1D 
gradient profiles [15] along the z-axis were recorded for each sample prior and post data 
acquisition. Duration of 90 degree pulses were automatically calibrated for each individual 
sample using a homonuclear-gated nutation experiment [16] on the locked and shimmed 
samples after automatic tuning and matching of the probe head.
Statistical analysis.
Each spectrum was integrated (binned) using 0.014 ppm integral regions between 10 
and 1 ppm, the residual water and urea region between 6 and 4.5 ppm was excluded, resulting 
in 550 data points used for the analysis. To account for any difference in concentration 
between the samples, each spectrum was normalized to a total area of 1. Absolute values 
were log-transforsmed. All pre-processing was done using in-house developed routines in 
R statistical environment (http://www.r-project.org/). Variables were centered and unit 
variance scaled prior to statistical analysis in SIMCA-P+ (version 12.0; Umetrics, Sweden) 
software package. For initial analysis and outlier detection, principal component analysis 
(PCA) was performed using 10 components. After the initial PCA analysis the following 
regions corresponding to paracetamol and its metabolites were excluded from the analysis: 
7.5 – 6.75, 3.95 – 3.8, 3.7 – 3.45, 2.2 – 2.14 and 1.84-1.88 ppm according to Bales et al. 
{17]. For partial least squares-discriminant analysis (PLS-DA)[18] samples were categorized 
based on classes as defined by the study design. PLS model was built using 5 categories 
according to logarithm of bacterial count as a Y variable. Statistical models from supervised 
multivariate data analysis were validated by random permutation of the response variable 
and comparison of the goodness of fit (R2Y and Q2) [19–20]. For random permutation 







model in a validation plot. Spectral regions responsible for the separation between classes 
in supervised models were identified based on the Variable Influence on Projection (VIP) 
values, which correspond to the importance of the variables (bins) for the model. The 
variables with a VIP value larger than 1.8 were considered significant and used for further 
analysis and identification of the responsible peak(s) within the spectrum. Prediction of class 
membership of samples by PLS-DA model was based on the predicted Y variable with the 
cut-off of 0.5.
For multilevel components analysis (MCA) using an in-house developed script in R as 
described by Jansen et al. [21] data were not log-transformed.
Univariate tests were performed to assess the statistical significance of the spectroscopic 
regions found using multivariate analysis: unpaired t-test was performed for the regions found 
as discriminating between UTI patients and controls by PLS-DA; ANOVA was performed 
on the regions that showed association with bacterial count in PLS; paired t-test was carried 
out on the regions identified in multilevel analysis. All the corresponding p-values were 
adjusted for multiple testing using Benjamini-Hochberg correction.
Identification of compounds of interest
Annotation of identified peaks was performed based on reference spectra from the 
Bruker Bioref database and in-house reference data. Confident identification was facilitated 
by the use of Statistical Total Correlation SpectroscopY method (STOCSY)[22].
Quantification of paracetamol
Quantification was performed by deconvolution and subsequent integration of 
paracetamol-glucuronide resonance at 5.10 ppm (d, 7.1 Hz) using an in-house developed 
automation routine. The absolute concentrations were calculated based on internal reference 
TSP. Values were not corrected for differential attenuation of the signals caused by relaxation 
during the mixing time and rapid-pulsing saturation effects.
RESULTS
The initial PCA on baseline samples revealed a trend in separation between UTI 
patients and controls in the scores plot of the first two principal components as shown 
in Figure 1A. However, we suspected that this could be due to over-the-counter (OTC) 
analgesics and antipyretics the patients might have taken prior to their visit to the hospital. 
Since paracetamol is one of the most commonly used OTC analgesic it was not surprising 
that we could find the major urinary metabolite of paracetamol, namely paracetamol-
glucuronide, present in higher concentration in many of the urine samples from UTI 
patients, whereas it was present only in low concentrations in very few of the control samples 
(Supplementary Figure 2). The absolute concentration of paracetamol-glucuronide was used 
to stratify samples in the PCA plot: the direction of increase of paracetamol-glucuronide 
was found to match the direction of controls-patients separation (Figure 1B). The variables, 
corresponding to paracetamol and its metabolites, also dominated the loadings plot in 
the direction of separation between UTI patients and controls. As paracetamol is not an 
infection or morbidity marker, the further analysis was performed after the exclusion of the 












































Figure 1. PCA scores plot of 1H NMR data from controls and UTI patients urine samples at 
baseline, first two principal components covering 14.5 and 10.2% of variation respectively. 
(A) Colored according to controls (□) and UTI patients (●). (B) Colored according to the 
logarithm of absolute concentration of paracetamol-glucuronide.
Figure 2. PCA scores plots of 1H NMR data from controls (black) and UTI patients (red) 
urine samples at baseline after removal of the regions corresponding to paracetamol and 
its metabolites. First principal component covers 11.7%, second 11.2% and third 9.8% of 
variation.
The PCA analysis of the baseline samples after the removal of spectral regions of 
paracetamol and its metabolites did not show separation between UTI patients and controls 
within the scores plot of the first two principal components; however, a clear trend was 







variability is to a certain extent more prominent than the disease effect. No outliers were 
detected based on distance to the model (DModX).
In the next step a supervised PLS-DA model was built for t=0 using UTI class as 
a response variable. In the scores plot of the resulting model the two groups were well 
separated (Figure 3). Cumulative explained variance (R2Y) of 0.88 and cross validated 
predictive fraction (Q2) of 0.63 were calculated for the model; the model validation plot 
showed intercepts of the R2Y and Q2 regression lines with the vertical axis at 0.63 and 
–0.11, respectively, indicating a valid model. Molecular discriminators were identified based 
on relevant regions as identified by the corresponding VIP. A list of those regions, along with 
the p-values based on t-test (corrected for multiple testing), the direction of change and 

























Figure 3. Cross-validated PLS-DA scores plot of urine 1H NMR spectra of controls (□) and 




Table 2. Spectroscopic regions that appear as influential in various statistical models and 
statistical significance of the corresponding univariate tests adjusted for multiple testing 
using Benjamini-Hochberg method.
Controls vs. UTI patients Bacteria concentration Recovery from t=0 to t=30








9.291 - 9.277 1-methylnicotinamide <0.0001 - <0.001 -
9.277 - 9.264 1-methylnicotinamide <0.01 -
8.977 - 8.964 1-methylnicotinamide <0.01 -
4.491 - 4.477 1-methylnicotinamide <0.01 - <0.01 -
1.941 - 1.927 Acetic acid <0.01 + <0.01 +
1.927 - 1.914 Acetic acid <0.0001 + <0.0001 +
3.196 - 3.182 Acetylcarnitine <0.01 +
2.568 - 2.555 Citric acid <0.01 -
2.541 - 2.527 Citric acid <0.01 -
4.082 - 4.068 Creatinine 0.03 -
3.073 - 3.059 Creatinine <0.01 - 0.07 -
3.059 - 3.045 Creatinine 0.09 -
7.709 - 7.696 Furoylglycine <0.01 +
7.696 - 7.682 Furoylglycine <0.01 - <0.01 -
3.959 - 3.946 Glycolic acid derivative <0.001 - <0.01 - <0.0001 +
7.859 -7.846 Hippuric acid <0.01 - <0.01 -
7.668 - 7.655 Hippuric acid <0.001 - <0.01 -
7.655 - 7.641 Hippuric acid 0.01 - 0.02 -
7.586 - 7.573 Hippuric acid <0.01 - 0.05 -
3.973 - 3.959 Hippuric acid 0.01 - 0.03 -
8.555 - 8.541 Hippuric acid (amide) <0.01 -
8.541 - 8.527 Hippuric acid (amide) <0.001 - <0.01 -
1.341 - 1.327 Lactic acid <0.01 + <0.01 +
7.764 - 7.75 Para-aminohippuric <0.001 +
3.332 - 3.318 Scyllo-inositol <0.01 +
3.455 - 3.441 Taurine <0.0001 + <0.001 + <0.0001 -
3.441 - 3.427 Taurine <0.0001 + <0.001 + <0.0001 -
3.427 - 3.414 Taurine <0.0001 + <0.01 +
3.264 - 3.250 Taurine <0.001 +
8.855 - 8.541 Trigonelline 0.01 +
4.45 - 4.436 Trigonelline <0.01 +
2.896 -2.881 Trimethylamine <0.0001 + <0.0001 +
8.486 - 8.473 Unknown <0.01 +
7.968 - 7.955 Unknown <0.001 +
7.75 - 7.736 Unknown <0.01 +
7.518 - 7.505 Unknown <0.01 +
6.686 - 6.673 Unknown <0.0001 +
6.509 - 6.496 Unknown 0.04 +
3.168 - 3.155 Unknown <0.01 -
1) two-group t-test for the healthy controls and UTI patients at baseline; positive direction of change corresponds 
to intensity of the region being higher in UTI patients compared to controls, negative – region intensity is lower in 
UTI patients compared to controls
2) ANOVA analysis for the number of bacteria present in urine; direction corresponds to the correlation to the 
number of bacteria: positive corresponds to the raise of the region intensity with the increase of the number of 
bacteria, negative - to the decrease of the region intensity with the increase of the number of bacteria 
3) paired t-test for the UTI patients at baseline and 30 days; positive direction of change corresponds to intensity of 








The advantage of PLS-based models is that they can easily be used to predict the class 
membership of new samples. Data of the UTI patients at t=4 were predicted using the 
two-class PLS-DA model that was built as described above. Of a total of 29 urine samples 
included in the prediction set, 19 (65.5%) were classified as controls, whereas 10 (34.5%) 
samples were classified as UTI (Figure 4). Besides using data from the 4-days time point as 
prediction set, we also performed a separate analysis for the 30-days time point (Figure 4). 
In this case, out of 37 samples collected, 32 (86.5%) were attributed to the group of controls 























Controls t=0 UTI patients t=0 UTI patients t=4 UTI patients t=30
Figure 4. Predicted response value for two-class PLS-DA model based on controls (black 
bars) and UTI patients (red bars) at baseline: blue bars are the t=4 and t=30 classified as 
controls, grey are the t=4 and t=30 samples classified as UTI patients at t=0.
An important parameter characterizing UTI patients is the number of bacteria in 
urine; however, bacteria can also be present in urine of the individuals, who do not exhibit 
any symptoms of UTI [23]. We built a PLS regression model from NMR data of urine at 
baseline using the result of bacterial culture as response variable. Since bacterial count and 
UTI classification do not fully correlate we expected to obtain a slightly different model 
as compared to the model built based on UTI classification for this timepoint. Using 2 
components a cumulative R2Y = 0.78 and Q2 = 0.44 were obtained and model validation 
showed intercepts of the R2Y and Q2Y regression lines with the vertical axis at 0.63 and 
-0.12, respectively, in the model validation plot. As can be seen from the PLS scores plot 
(Figure 5) the samples with the highest bacteria concentration in urine were very distinct 
from the rest forming a separate cluster, whereas the rest of the samples were overlapping. 
The spectral regions responsible for the correlation of the 1H NMR data and bacterial count 
were chosen on the basis of the corresponding VIP. A list of those regions, along with the 
p-values derived from ANOVA (corrected for multiple testing), the direction of change and 































Figure 5. Scores plot of the PLS model of urine 1H NMR spectra at baseline vs. the number 
of bacteria (CFU/mL) found in urine (R2Y = 0.78, Q2 = 0.44). Colored by the number of 
bacteria.
To better understand the process of patient recovery and to find the spectroscopic 
regions that correlate with this process, we took advantage of the longitudinal study design. 
One of the statistical methods suitable for such analysis is multilevel component analysis 
(MCA) that separates variation present in the data into two levels: between-individual and 
within-individual. We performed this analysis on the 29 patients for which both the data 
from the baseline and from the 30-days time point were available and concentrated on the 
within-individual information. This should best reflect the recovery from the baseline, when 
patients are diagnosed as infected, to 30 days, when they are considered UTI symptom-free. 
PCA scores plot of the first two principle components that cover 15.8 and 14.8% of the 
variation, respectively, showed good separation between baseline and t=30 time points (data 
not shown). The PLS-DA model of this data had high quality parameters (R2Y = 0.98, Q2 = 
0.96 for four components), showed stability in permutation test (intercepts of the R2Y and 
Q2 regression lines with the vertical axis were at 0.42 and -0.6, respectively) and perfectly 
separated the two time points (data not shown). The NMR spectral regions responsible 
for the separation between baseline and the t=30 time point were identified based on VIP 
values. The underlying metabolites as well as the p-values from paired t-test (corrected for 
multiple testing) and the direction of change are summarized in Table 2. 
DISCUSSIONS
UTI represents a complex clinical entity, for which diagnostics is not straightforward: 
there is no single test or criteria for it [7]. In the current paper we approach identification 
of metabolites that characterize UTI and its pathology with the use of 1H NMR. We 
demonstrate how the use of clinical data and multiple samples per individual can enrich 







UTI research, as a first attempt the smaller selection of UTI subjects from a bigger cohort 
was used, with similar diagnosis and with the major pathogen being E. coli. A set of matched 
controls was also available.
Unlike in animal experiments, in clinical research assigning people to certain groups is 
not always unconditional. The diagnosis of a disease can be fuzzy and defining the ‘healthy’ 
group is even more difficult, as there is hardly a definition of healthy. Thus, it may be very 
advantageous to supplement a traditional ‘case-control’ design with a more complex study 
design and the use of additional clinical data. When used without extra information, ‘case-
control’ analysis might even be misleading. For example, the separation of the control 
and UTI groups was seen in the first two principal components of PCA; however, this 
discrimination was not disease-related, but the result of patients taking the antipyretic and 
analgesic drug paracetamol. An analysis strategy for such type of data is to identify all of 
the spectroscopic regions that contain signals from drug-related compounds and to exclude 
them prior to further analysis. However, it is not feasible to account for the whole range of 
the medication used and, more importantly within the context of clinical metabolomics 
studies in general, to account for drug-related shifts in metabolism, especially in the case of 
long-term treatment regimes of chronic conditions. It is essential to consider such effects 
when developing the study design in order to minimize or control such influences.
Samples from 4 days after admission, when the patients were still under therapy, but on 
the way to recovery, were used to check if the modeled differences were related to the effect 
of medication or not. The fact that the majority of those samples were classified as healthy by 
the model built on baseline samples is an indication that the model is not reflecting therapy/
drug intake, but is indeed related to the clinical difference between the groups.
The samples from the 30-days time point, when UTI patients were symptom-free, 
could also be used to gain additional information on the performance of the model as well 
as to get insight into the underlying biology. When predicted using the PLS-DA model 
built on the baseline UTI infected and UTI symptom-free samples, most of the 30-days 
samples (86.5%) were projected to the control group. Those few, which were still predicted 
as infected UTI patients, may have another condition (as we do not know at this point how 
specific our model is) or have asymptomatic UTI. On the other hand, they can be healthy 
and be false positives, as the predictive ability of our model, estimated by cross-validation 
was 63%. Despite that, considering the prediction of 30-days samples as an independent 
statistical test for our model, it gives very satisfactory results. 
Pair-wise analysis for baseline and 30-days samples from the same individuals was 
conducted in order to monitor the recovery process. It revealed a number of classifiers 
and improved their statistical significance. The identified metabolites overlapped with the 
compounds from the model discriminating healthy and UTI subjects, however a few of them 
were unique (para-aminohippuric acid, scyllo-inositol and a few unidentified compounds).
Besides the multilevel design, the advantage of the current study was the exhaustive 
clinical characterization of the patients. Among the variety of clinical parameters available, 
the number of bacteria in urine was of specific importance. We performed regression-
based analysis of the relation between the 1H NMR data and the bacterial load in urine 
as determined by bacterial culture. The classifiers that emerged from this analysis were to 
a certain extent overlapping with the classifiers derived from the discriminative model on 
baseline samples. This was no surprise, since UTI is generally characterized by the presence 




When comparing the lists of discriminators obtained from the different models 
(discriminating UTI patients from controls, modeling the recovery process and modeling 
the data against the degree of bacterial contamination of urine) it is evident that there is a 
large overlap which makes biological interpretation of the results feasible. For instance, some 
of the overlapping metabolites were already known from the literature to be related to the 
bacterial contamination of urine: acetate, lactate and trimethylamine [9]. Others, if they 
were found only in the comparative analysis of the two groups, could be attributed based on 
previous studies to certain phenomena. Hippuric acid, for example, is often associated with 
the gut microflora [24] and taurine with liver toxicity [25]. However, our findings suggest 
that they are also associated with the bacterial contamination of urine, which obviously does 
not mean that they are not related to the mentioned physiological processes as well, but that 
a complex network of interconnected factors is involved. The metabolites that appear to be 
related to the recovery process might be considered as potential morbidity markers. One 
of them, para-aminohippuric acid, is a well-established diagnostic marker for renal plasma 
flow and glomerular filtration [26]. The recovery from the complicated, tissue-invasive UTI 
is associated with the resumption of the kidneys’ function, so the positive change in para-
aminohippuric acid corroborates our assumption that some of the markers discovered in the 
paired analysis are the markers of morbidity.
CONCLUSION
In the current paper we used a metabolomics approach to profile UTI, which is on the 
one hand one of the most common infectious diseases among the adults, and on the other 
hand a disease that still lacks markers of morbidity. Using 1H NMR profiles of urine we 
generated various statistical models: (a) discriminating UTI patients and control subjects, 
(b) following the recovery process of UTI patients and (c) associating urine metabolic 
content with bacterial contamination. The discriminative model was able to classify most 
of the independent samples correctly according to their diagnosis, which indicates its high 
predictive ability. Comparing the sets of molecules derived from different analyses, we 
concluded that some of the compounds (e.g. trimethylamine and acetate) can be attributed 
to the effect of bacterial contamination of urine; others (e.g. para-aminohippuric acid, 
scyllo-inositol) can be considered markers of morbidity.
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Supplementary Figure 1. Design of the study.





















Supplementary Figure 2. Paracetamol-glucuronide doublet in baseline samples colored by 
controls (black) and UTI patients (red).
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Urinary tract infection (UTI) is the most common bacterial infection leading to 
substantial morbidity and considerable health care expenditures across all ages. Here 
we present an exploratory UPLC–MS study of human urine in the context of febrile, 
complicated urinary tract infection aimed to reveal and identify possible markers of a 
host response on infection. A UPLC–MS based workflow, taking advantage of Ultra High 
Resolution (UHR) Qq-ToF-MS, and multivariate data handling were applied to a carefully 
selected group of 39 subjects with culture-confirmed febrile Escherichia coli UTI. Using 
a combination of unsupervised and supervised multivariate modeling we have pinpointed 
a number of peptides specific for UTI. An unequivocal structural identification of these 
peptides, as O-glycosylated fragments of the human fibrinogen alpha 1 chain, required MS2 
and MS3 experiments on two different MS platforms: ESI-UHR-Qq-ToF and ESI-ion trap, 
a blast search and, finally, confirmation was achieved by matching experimental tandem 
mass spectra with those of custom synthesized candidate-peptides.
In conclusion, exploiting non-targeted UPLC-MS based approach for the investigation 
of UTI related changes in urine, we have identified and structurally characterized unique 
O-glycopeptides, which are, to our knowledge, the first demonstration of O-glycosylation of 





Urinary tract infection (UTI) is the most common bacterial infection leading to 
substantial morbidity and considerable health care expenditures across all ages [1]. The 
term ‘urinary tract infection’ encompasses a variety of clinical syndromes with the common 
denominator of a positive urine culture (i.e., significant bacteriuria ≥ 103 CFU/ml) [2]. 
Pathogens most commonly associated with UTI are Enterobacteriacaea such as Escherichia coli, 
Klebsiella pneumoniae, Proteus sp. and Staphylococcus saprophyticus. In a first approximation, 
UTI can be grouped into acute uncomplicated UTI (non-pregnant young women with 
cystitis but no evidence of urological abnormalities) and complicated UTI (UTI in males, 
all febrile UTI syndromes and those with urological abnormalities) [3, 4]. In this respect, 
fever reflects the presence of a tissue invasive disease such as pyelonephritis, prostatitis 
or the urosepsis syndrome. A clinical management of UTI is rather straightforward and 
implementation of modern analytical technologies such as mass spectrometry for diagnostic 
purposes will have little impact on the clinical decision making. However, mass spectrometry 
might provide new, highly needed input in scaling the morbidity inflicted to, for example, 
prostate or kidney or obtaining guidance for duration of the treatment.
So far, the most successful application of mass spectrometry in the context of UTI 
was the identification of a pathogen. Ferreira et al [5] have shown that matrix-assisted laser 
desorption ionization–time of flight mass spectrometry (MALDI-ToF MS) in combination 
with pattern recognition algorithms can provide a correct pathogen identity in more than 
90% of cases with bacteriuria cut-off at 105 CFU/ml. In general, MALDI-ToF MS has 
quickly evolved as a method of pathogen identification and took its place in microbiological 
laboratories alongside with more classical techniques [6]. However, for an unbiased 
exploratory study, which is needed for a first evaluation of the host response to UTI, a 
hyphenated technique as, for example, liquid chromatography–mass spectrometry (LC–MS) 
is probably a better choice. Those techniques cover a broad range of chemical entities and 
most importantly a very special group of compounds such as small molecules and naturally 
occurring urinary peptides. The clinical relevance of the last ones was proven in a large scale 
study of Good et al [7]. Here, we present a first exploratory LC–MS study of human urine 
in the context of febrile, complicated urinary tract infection. Using a carefully matched 
selection of patients with infection due to E. coli, we have evaluated the applicability of a 
reverse phase (RP)UPLC-ToF-MS approach for UTI in a clinical study and identified a 
glycopeptide representing a unique proteolytic fragment of the fibrinogen alpha 1 chain as a 
possible marker of active UTI.
EXPERIMENTAL SESSION
Chemicals
Ethanol, methanol (HPLC grade) and formic acid were purchased from Sigma-Aldrich 
(Zwijndrecht, The Netherlands). Sodium hydroxide was purchased from Fluka (Zwijndrecht, 
The Netherlands). Peptides were synthesized at the LUMC-facility as described previously 
[8].
Clinical samples







of eight emergency departments (ED) of seven hospitals and 35 affiliating primary health 
care providers. From January 2004 through November 2008, patients who presented with a 
diagnosis of febrile UTI, were considered for enrolment in the study. The study was approved 
by the local ethics committees and all included patients gave written informed consent. 
Inclusion criteria and exclusion criteria have been described in detail elsewhere [9,10]; in 
short, patients of 18 years or older, with fever and presenting at least one symptom of UTI 
(dysuria, frequency, of urination, perineal pain, flank pain or costovertebral tenderness) and 
a positive nitrite dipstick test or a positive leukocyte esterase dipstick test were enrolled. 
Exclusion criteria were current treatment for urolithiasis or hydronephrosis, pregnancy, 
hemo- or peritoneal dialysis, a history of kidney transplantation or known presence of 
polycystic kidney disease. Details with respect to empiric therapy and follow-up are provided 
elsewhere [11]. Urine samples were collected at enrolment as baseline samples (t=0). After 
three (t=3) and thirty days (t=30) urine samples of the same patients were collected for 
follow-up. Clean midstream-catch urines were collected and stored, within 2 h after the 
collection, at -80° C until further analysis. Bacterial cultures were obtained at all time points 
and were analyzed using standard microbiological methods. A positive urine culture was 
defined as bacterial growth of over 103 colony-forming units per ml2.
For the current study, from a database of about 700 subjects enrolled, a group of 39 
subjects with culture-confirmed E. coli in the urine was selected. Samples from volunteers 
without UTI or symptoms of infection were enrolled as negative control (a negative bacterial 
culture; no evidence of inflammatory disease) and in this study used as references. Baseline 
characteristics of the samples are presented in Table 1. The study design includes the control 
samples and samples of UTI patients collected at baseline (t=0) as well as patient samples 
collected after the antibiotic treatment (t=30).
Table 1. Baseline characteristics. Data are presented as n (%) unless otherwise stated. IQR: 
interquartile range.
Characteristics Casesn = 39
Controls
n = 39 p
Age, years, median [IQR] 59 [42-70] 58 [49-67] 0.900
Male sex 18 (46) 18 (46) 1.000
Smoking 5 (13) 5 (13) 1.000
Co-morbidity
Urinary tract disorder 4 (10) 4 (10) 1.000
Malignancy 4 (10) 1 (3) 0.166
Heart failure 5 (13) 3 (8) 0.456
Renal insufficiency 1 (3) 0 (0) 0.134
Diabetes mellitus 6 (15) 2 (5) 0.136
Immunocompromised 1 (3) 1 (3) 1.000
Urine dipstick results 
Nitrate 26/36 (72)* 0/36 (0)* < 0.001
Leucocyte esterase 35/36 (97)* 5/36 (14)* < 0.001
*: 3 missing values
Sample processing
Samples were prepared for non-targeted analysis of small molecules and natively 
occurring urinary peptides. Protein precipitation was carried out by adding 75 µl of cold 




were centrifuged at 3660 g for 10 min and the supernatant was collected and evaporated 
until dryness overnight. The samples were then reconstituted with 100 µl of water and 10 µl 
was used for injection. The injection scheme was randomized and it included quality control 
samples (fresh voided urine samples prepared in the same way as the clinical samples) to 
ensure the robustness of the workflow and to evaluate the analytical variability. The total 
number of 117 clinical samples was organized in 4 sequences (4 injection days); two quality 
control samples were injected at the beginning, at the end and after every six biological 
samples. In total, 165 samples (48 quality controls plus 117 clinical samples) were analyzed 
by UPLC-ESI-Qq-TOF MS (Ultra High Resolution ToF, maXis, Bruker Daltonics, Bremen, 
Germany). The UPLC (Ultimate 3000 RS tandem LC system, Dionex, Amsterdam, The 
Netherlands) was equipped with a pre-column (Acclaim 120 C18, 5 µm, 120 Å, and 2.1 
x 10 mm,) and two analytical columns (Acclaim RSLC 120 C18, 2.2 µm, 120 Å, and 2.1 
x 100 mm) working alternatively to speed up the acquisition series. The UPLC flow was 
set at 400 µl/min and the mobile phases were water + 0.1 % formic acid v/v (Phase A) and 
methanol + 0.1% formic acid v/v (Phase B). The gradient was as follows: 1 min 0 % phase B, 
then in 1 min to 10% phase B, held for 1 min at 10% phase B, and subsequently in 6.5 min 
to 100% phase B and held for 3 min at 100% phase B. Before each chromatographic run, a 
calibrant solution of sodium formate was injected in flow injection mode.
The mass spectrometer was operated in positive ionization mode and acquired data 
in the mass range from m/z 50 to 1000 with a spectra rate of 1 Hz. The capillary was set at 
4500 V, the end plate offset at -500 V, the nebulizer gas at 2 bars and the dry gas at 8 L/min 
at 200°C.
For compound identifications MS2 and MS3 experiments were performed using ESI-
ultra high resolution UHR-Qq-ToF and ESI-ion trap MS (HCTultra, Bruker Daltonics). 
The data were acquired in a wider scan range from m/z 50 to 2000 in auto MS/MS mode 
and by using an inclusion list of precursor ions of interest (the ones relevant after statistical 
data analysis). Collision energies were the following: m/z 500 (singly charged) 50 V, m/z 500 
(doubly charged) 30 V and m/z 1500 (singly charged) 35 V, and m/z 500 (doubly charged) 
25 V. All the m/z values within this interval were fragmented with interpolated values of 
collision energy.
MS3 experiments were performed using a reverse phase LC-ESI-ion trap MS system 
as described previously [12] with slight modifications. For electrospray (1100–1250 
V), stainless steel capillaries with an inner diameter of 30 mm (from Proxeon, Odense, 
Denmark) were used. The solvent was evaporated at 170°C employing a nitrogen stream of 
7 L/min and ions from m/z 500 to 1800 were registered. Automatic fragment ion analysis 
was enabled resulting in MS/MS spectra of the most abundant peaks. The two most intense 
ions of each MS/MS spectrum were subjected to an additional ion isolation/fragmentation 
cycle, resulting in MS3 fragment ion spectra.
Data analysis
The LC–MS data files were exported as mzXML files and aligned by using the in-house 
developed alignment algorithm msalign2 tool [13] (http://www.ms-utils.org/msalign2/); 
peak picking was performed using XCMS package (The Scripps Research Institute, La 
Jolla,USA) using the default settings except for bandwidth (bw parameter) for grouping of 







The generated data matrix was imported to the SIMCA-P 12.0 software package 
(Umetrics, Umeå, Sweden). The data were mean centered and unit variance-scaled prior 
to statistical analysis. The validity and the degree of overfitting of the PLS-DA models were 
checked using a 200 permutations test.
To identify metabolites of interest, rational chemical formulas were generated 
based on internally calibrated monoisotopic masses within 10 mDa mass error, using the 
SmartFormula tool within the DataAnalysis software package (Bruker Daltonics).
RESULTS
Considering the fact that the presented study is the first exploratory LC–MS study 
of human urine in the context of febrile urinary tract infection, a general overview of the 
analytical consistency of the method was the starting point of the data analysis. To evaluate 
the effect of analytical variability, we performed Principal Component Analysis (PCA) using 
the whole data set of clinical and quality control samples (165 samples). Figure 1 shows the 
PCA score plot for the first two principal components. No analytical trends, such as day 
of injection, injection sequence or influence of the column, were represented in the first 
three principal components, which altogether cover 46% of the total variation. Thus, the 
analytical variability within our data set had negligible influence on the data matrix.
Figure 1. Scores plot of the PCA analysis of the entire data set (including quality control 
and clinical samples).
Subsequently, we removed the quality control samples from the model and we focused the 
data analysis on clinical samples. We observed a clear separation of UTI patients and UTI 
free subjects (Controls and t=30 days) in the PCA model (Supplementary Figure 1A). A 
two-class PLS-DA model built on baseline samples (controls and patients at t=0 days) had 
satisfactory values of goodness of fit and prediction ability (Supplementary Figure 1 B). The 
analysis of Variables Importance on the Projection values (VIP) higher than 1.5 revealed 




affected by febrile UTI. Taking advantage of the intrinsic properties of the UHR-Qq-ToF 
instrument such as the high mass accuracy and the high-confidence resolution of isotopic 
distribution we could identify glucuronide (C14H17NO8), acetaminophen mercapturate 
(C11H14N2O4S) and N-acetylacetaminophen mercapturate (C13H16N2O5S) (Supplementary 
Figure 1C, Supplementary Table1). These data were confirmed by our internal database in 
which the use of fever reducers was reported for those subjects.
Figure 2. Statistical models of the LC-Qq-ToF-MS data. A) PCA and B) PLS-DA with Q2 
(cum)=0.520 and R2Y (cum)=0.647. Samples are coloured according to the disease status.
It is evident that the metabolites of acetaminophen introduce a bias in the data 
concealing the effects relevant for the study. Therefore, we removed all variables related to 
acetaminophen metabolites from our dataset and re-analyzed the data. The PCA model built 
on this neatened data matrix did not show such a clear separation between infected and 
uninfected patients as in the previous model (Figure 2A). However, a visual trend for such a 
separation was evident. The goodness of fit and prediction values for the new two-class PLS-
DA model built on baseline samples (t=0 days and controls) were lower (Figure 2B), but for 
human studies still within the statistically acceptable limits. The 30 days after enrolment 
samples were used to test the predictive power of a model: 34 of 39 samples were predicted 
as recovered patients, clustering with the group of not infected subjects. An overview of 
the VIP values > 1.5 revealed 40 features. After closer examination, half of them could be 
organized in three groups according to their retention times (Table 2). 
Table 2 List of major classifiers expressed as m/z with their retention times and VIP>1.5 in 
bracket.
Group Retention time (s) m/z (VIP Value)
1 58.3 747.274(1.79) 675.239(1.81) 676.248(1.81) 672.174(2.21) 657.232(1.55) 292.103(1.67)
2 382.4 875.361 (1.78) 876.365(1.78) 877.37(1.77) 584.266(2.12) 375.211(1.74) 366.139(2.07) 292.103(2.11) 274.093(2.12)







Within the MS spectra of groups 1 and 2, we observed ions corresponding to some 
putative in source fragmentation of glycan moieties. Classifier 1 appeared to be a free 
sugar moiety composed of a sialic acid, one hexose and one N-acetylhexosamine (Figure 
3A). Classifier 2 (Figure 3B) contains a similar glycan moiety most probably on a peptide 
backbone of 218.127 Da which can represent either the dipeptide threonine–valine or the 
dipeptide serine–(iso)leucine.
Figure 3. Mass spectrometric characterization of the major classifiers. MS spectra of 
the classifiers from group 1 (A) and 2 ( B ). MS2 spectrum of m/z 816.86 belonging to 
group 3 (C) with the work flow for its identification (D) combining information from the 
fragmentation spectrum, BLAST searches and data from synthetic peptides.
To identify classifier 3, we performed MS/MS experiments using two different 
mass analyzers: UHR-Qq-ToF and ion trap to take advantage of the characteristics of 
each respective analyzer. We started the structural assignment form the largest identified 
precursor. MS/MS data were acquired selecting as precursor the double charged ion at m/z 
816.86 (Table 2, Group 3) on the UHR-Qq-ToF (Figure 3C). The identification workflow 
is shown in Figure 3D. The fragmentation pattern revealed characteristics of a glycopeptide 
based on the sequential losses of two sialic acids (NeuAc; m/z 1050.5315), one hexose 
(Hex; m/z 888.4656) and one N-acetylhexosamine (HexNAc; m/z 685.3869). According 
to the literature [15-18] this most probably reflects a typical core-1 type O-glycan structure 
composed of Gal1GalNAc1NeuAc2. The peptide backbone was represented by the ion at m/z 
685.3869. Apparently, some peptide backbone cleavages also occurred, resulting in the ions 
at m/z 570.3222 and 483.2897. Using the mass accuracy of the UHR-Qq-ToF-analyzer, we 
assigned these ions as b-type ions generated after the sequential loss of a terminal proline 




terminal aspartic acid (exact mass difference 115.0269 Da) and a serine. The loss of proline 
was also observed after the initial loss of 185.1173, resulting in an internal fragment ion. In 
this case, the accurate mass points towards the loss of the dipeptide glycine–lysine (GK/KG, 
exact mass 185.1164). To further corroborate that the above mentioned ions were indeed the 
result of peptide backbone fragmentation, an MS3 spectrum from the ion at m/z 685.4 was 
recorded using ESI-ion trap MS (Supplementary Figure 2A). Assuming that the loss of the 
glycine–lysine dipeptide was the result of a cleavage N-terminal of a proline, we predicted 
that the peptide backbone should have the sequence (GK/KG)P(200.1151 Da)SP. The 
total mass of the two remaining amino acids (200.1151 Dalton) matches with a dipeptide 
consisting of (iso)leucine–serine or threonine–valine (which have the same elemental 
composition with an exact mass of 200.1161 Dalton). Therefore, we performed BLAST 
searches against the human NCBI database, taking all the above possibilities into account. 
This resulted in two positive identifications; one (GKPSLSP) corresponding to a peptide 
from the C-terminus of fibrinogen alpha 1chain (GI 11761629) and one (KGPSLSP) 
to an unnamed protein product (GI 22760358). No positive matches were found when 
identical BLAST searches were performed against the E. coli database. To discriminate 
between the two above mentioned possibilities we synthesized both peptides, performed 
MS/MS experiments on the ion trap and compared the fragmentation patterns with the MS3 
spectrum that we obtained from the urinary glycopeptide (Supplementary Figure 2B and C). 
This unambiguously showed that the glycopeptide we have identified corresponded to the 
C-terminal peptide from fibrinogen alpha 1 chain (GKPSLSP). At this stage we can relate 
group 2 (see above) as putative derivative of this same peptide containing the dipeptide SL/
LS carrying the glycan moiety. Finally, using integrated peak areas for the ion at m/z 816.86 
we constructed a box plot, which clearly demonstrated the differences between the patients 
with an active UTI status, the recovered group (t=30) and the control group (Figure 4).
Figure 4. Box plot displaying the differences of peak area related to m/z 816.86 in the model 
classes.
DISCUSSION
Here we present the first exploratory UPLC-MS based study of UTI. As clinical entity 
UTI includes a number of syndromes in which the only common feature is a positive 







Enterobacteriacaea such as E. coli, K. pneumoniae, Proteus sp. and S. saprophyticus. Thus, to 
minimize sample variability we have selected for the current study only the patients with 
culture-confirmed febrile E. coli UTI (Table 1).
Using a combination of unsupervised and supervised multivariate modeling we have 
selected forty most significant variables according to their VIP values. Approximately half 
of them could be grouped into three chromatographic peaks. A close examination of the 
spectra revealed the possible structural similarity of these three peaks with the peak at 410 
s containing the most complete structure. The identification of this peak (m/z 816.86) as 
a product of proteolytic degradation of one of the most abundant serum proteins (human 
fibrinogen alpha chain isoform 2) may not seem encouraging at the first glance. The 
increased release of fibrinogen fragments in urine as a response to an infection or infection 
related kidney damage has little novelty. It was reported for the first time in the seventies 
and confirmed many times afterwards [7, 19-22]. Yet, the fact that this C-terminal peptide 
of fibrinogen alpha chain is carrying an O-glycan turns it into a rather unusual finding. 
Human fibrinogen alpha 1-chain was considered to be free of glycosylation, and only the 
alpha 2 isoform which is a splice variant with an elongated C-terminus has been shown to 
be N-glycosylated upon expression in  monkey cells (COS cells) [23]. The proposed glycan 
structure corresponds to a T-antigen — core 1 type disaccharide Galβ1-3GalNAcα1 — 
which may carry 0, 1, or 2 sialic acid moieties. Such (partially) sialylated T-antigen structures 
are commonly found on various glycoproteins such as, for example, apolipoproteins [15-
18]. There is only a single report by L’Hôte et al. which indicated a similar modification on 
porcine fibrinogen alpha chain on the basis of analysis with a combination of lectins [24]. 
However, neither the structure of the glycan nor the site of glycosylation was identified. In 
our case a combination of the data sets generated with the help of two mass analyzers and an 
additional confirmation using a synthetic peptide helped us to identify the exact sequence 
of the peptide backbone, although the question whether serine 641 or serine 643 carry the 
glycan moiety remains open.
Thus, our findings lead to a modification of the existing concept of fibrinogen structure. 
As an essential part of one of the most important physiological defense systems in the human 
organism, fibrinogen has been studied rather well. Nevertheless till now the alpha 1 chain was 
considered to be free of glycosylation. One might argue that the bulk of the work was done 
on the hepatic fibrinogen, which represents approximately 70% percent of total fibrinogen 
[25]. The peripheral tissues are capable to produce the ‘localized’ isoforms of fibrinogen 
as well; however, data on their structure and physiological significance remain scarce. An 
unusual O-glycosylation might be interpreted as an indication of the extra-hepatic origin of 
the fragments. However our data do not provide evidence for tracing of the physiological 
origin of this fragment and the question whether it is derived from hepatic or peripheral 
fibrinogen remains open. 
It is well known that in healthy individuals the loss of fibrinogen through the coagulation 
cascade accounts only for 2% or 3% of total plasma fibrinogen [26]. Consequently, the 
peptides described in our study might well be filtrated from blood or proteolytically 
converted in the lower urinary tract or even be a result of urinary fibrinolytic activity. It has 
been shown that granulocytes possess a set of neutral proteases capable to use fibrinogen as 
a substrate [27]. In view of the involvement of granulocytes in antibacterial host defense the 
appearance of such proteolytic fragment in urine might then be considered as an indication 




can only be speculative, a simple comparison of peak areas in each of three groups shows the 
difference between the group of patients with clear UTI symptoms (t=0) and the groups of 
the symptom free patients (controls and t=30).
In conclusion, using non-targeted exploratory UPLC–MS based approach for the 
investigation of UTI related changes in urine, we have identified and structurally characterized 
a unique C-terminal glycopeptide of the human fibrinogen alpha-chain, which to our 
knowledge is the first demonstration of glycosylation of alpha-chain. Of course, clinical 
significance of this finding should be evaluated on the larger cohort. Indeed, on the basis of 
the presented results we are now analyzing Leiden prospective UTI cohort of 700 samples.
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Supplementary Figure 1. Models of LC-Qq-ToF-MS data: A) PCA and B) PLS-DA, two 
class model built using baseline patients (t=0) and control (Q2 (cum) = 0.598 and R2Y 
(cum) = 0.686) with t=30 group used as a validation set. Samples are colored according to 
the disease status. C) A representative base peak chromatogram of urine sample collected at 
t=0; the peaks marked as a, b and c correspond to acetaminophen metabolites. In details: a) 




Supplementary Figure 2. Peptides MSn spectra. A: Group 3, MS3 of urinary glycopeptide 
on ESI-Ion trap. B and C: MS2 on ESI-Ion trap at m/z 685.7 of two synthetic peptides. The 
spectrum B resembles better the urinary peptide fragmentation showed in the spectrum A.
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With a development of the metabolomics field, complementary cross-platform 
approaches started to attract attention, as none of the contemporary analytical methods had 
the capacity to cover the entire space of the human metabolome. In the current manuscript, 
we have evaluated an online coupling of gas chromatography (GC) – mass spectrometry 
(MS) and flame ionization detector (FID) as way of cross-detector analysis. The possible 
value of this combination was recognized from the very first days of GC-MS history but 
was never explored in detail. We have compared the basic analytical parameters of both 
detectors, such as limit of detection (LOD) and limit of quantification, with intra- and 
interday reproducibility. We show that for the majority of the tested compounds, MS 
detector demonstrates lower LOD. At the same time, FID appeared to be more robust, 
showing lower relative standard deviations (RSDs) for intra- and interday reproducibility. 
We conclude that the gain of this dual detector acquisition appears to be most evident for 
complex biological samples, where wide dynamic range and predictable response of FID 
are useful for an initial quantitative overview of sample composition and estimation of 
molar proportions of different metabolites. MS provides reliable, structural information and 
superior, at least in the case of atmospheric pressure chemical ionization, sensitivity. Taken 
together, both detectors represent a flexible tool for explorative studies and if supported by 






The concept of metabolomics as a global overview of an organism’s metabolites emerged 
in the early 1970s [1, 2], and from the beginning, it was evident that its technical realization 
demands complementary methodologies, as none of the contemporary analytical methods 
had the capacity to cover the entire space of the human metabolome. Despite the booming 
development of this field, 40 years later, we are still facing the same problem. 
A classical way to expand the set of analyzable compounds –coming from different 
chemical families and with different molecular weights (MWs)– and their linear dynamic 
range is the use of multidimensional chromatography. In routine analysis, multidimensional 
chromatography is usually divided in heart-cut and comprehensive approaches [3]. The 
latter one is of primary importance for metabolic profiling, as it implies the separation of 
the complete sample in both chromatographic dimensions. A combination of two or more 
stationary phases leads to the exhaustive fractionation of the sample and eventually helps 
to use the dynamic range of the detector, usually a mass spectrometer, more efficiently. 
Multidimensional comprehensive chromatography is a relatively time-consuming method, 
and the depth of the coverage is proportional to the analysis time. When expensive, high-end 
mass spectrometry (MS) instruments are used as detectors, this can be a disadvantage. In 
addition, multidimensional comprehensive chromatography is, in practice, a single detector 
method, and regardless of the fractionation quality, the physical properties of the detector 
are the factors that ‘constrain’ the analysis. In the case of MS, those factors are the ionization 
technique and the type of mass analyzer. An alternative way to extend the coverage of 
the metabolome is a cross-platform analysis. The essence of cross-platform analysis is the 
acquisition of data using instruments with entirely different physics of detectors, followed 
by post–acquisition data fusion. A classical example is a combination of NMR spectroscopy 
and MS. NMR is, without reservation, the most powerful method of modern metabolomics 
[4-6]. With regard to metabolic profiling of body fluids, 1H-NMR, which provides a 
fingerprint of proton-containing species, has become a routine tool. Moreover, NMR 
is probably the only analytical method where quantitative and structural information is 
‘embedded’ in the physics of the detector. Still, a coanalysis of NMR with MS data expands 
the analytical domains of both methods and opens new ways of data interpretation [7]. 
For example, it has been shown that application of correlation-based algorithms, such as 
statistical heterospectroscopy (SHY) can be a useful way to dissect and structurally resolve 
xenobiotic metabolites in human body fluids [8].
The combination of NMR and MS is undoubtedly a powerful platform, but it requires 
costly instrumentation (NMR) and specialized expertise. In the current manuscript, we 
propose a way of cross-detector analysis, which can be practiced in almost any analytical 
laboratory: a combination of gas chromatography-mass spectrometry (GC-MS) and flame 
ionization detector (FID). GC is, without doubt, one of the most important and widely 
applied techniques in modern analytical chemistry, and FID has often been the first choice 
for GC routine analysis of complex biological samples. Indeed, since its introduction in 
1958, FID has quickly become the most popular detector for GC and not without a reason: 
FID responds practically to all organic compounds, it is resistant to small fluctuations of 
the gas flow, it is insensitive to gas impurities, and most importantly, the FID response is 
very predictable, obeying the rule of equal carbon response [9]. The additional value of a 
combination of MS and FID has been  recognized already in the early days of GC-MS 







metabolic profiling studies has been demonstrated once more [12]. However, in practice, the 
combination of GC-MS and GC-FID has never developed into a routine analytical method, 
and there are a number of explanations for this. One of these is that for routine analytical 
applications, the benefits were not clearly obvious, and at the same time, technical issues 
with the synhronization of FID and vacuum-stage MS were considerable [11, 12]. With 
the reintroduction of Atmospheric Pressure (AP) sources for GC-MS [13, 14], the technical 
problems preventing optimal use of a combination of MS and FID have been largely 
overcome. In the current study, we demonstrate not only the simplicity of the coupling but 
also the possible complementarities of both detectors, in particular, for explorative studies 
about complex biological samples. 
MATERIALS AND METHODS
A standard solution of 17 amino acids at 1 mM each in 1 M HCl was purchased from 
Sigma–Aldrich (Zwijndrecht, Nederland). Dopamine hydrochloride and phenyl-glycine 
(Phe-Gly) hydrate were from Fluka (UK). Sarcosine, theophylline, caffeine, nortriptyline 
hydrochloride, hippuric acid, 4-O-methyldopamine hydrochloride, benzoic acid, uric acid, 
and 5-hydroxyindole-3-acetic acid were acquired from Sig ma-Aldrich. Stock standard 
solutions of the 28 compounds were prepared in methanol at a concentration of 200 mM. 
N-methyl-N-trimethylsilyltrifluoroacetamide plus 1% trimethylchlorosilane (MSTFA + 1% 
TMS) were used as derivatization reagents (Pierce, Rockford, IL, USA). These reagents were 
used from freshly opened 1 ml bottles. Methoxyamine hydrochloride was purchased from 
Supelco (Park Bellefonte, PA, USA). Methanol (HPLC grade) and acetonitrile (GC grade) 
were acquired from Sigma-Aldrich, and pyridine (>99%, ultra-pure GC grade) was from 
Fluka. 4-Chlorophenol, decylamine, methyl caprate, prometryn, aldrin, and endosulfan 
α were purchased from Sigma-Aldrich. Stock solutions of these analytes were prepared in 
acetonitrile at a concentration of 10 mM. Reserpine was purchased from Sigma-Aldrich.
Sample preparation.
Aliquots of the standard mix were evaporated and derivatized by adding 100 
ml methoxyamine (60 min, 40°C) and subsequently, 50 ml MSTFA (30 min, 40°C). 
Cerebrospinal fluid (CSF) samples were taken by lumbar puncture. The study was approved 
by the Ethical Committee of the Leiden University Medical Center (The Netherlands). 
Samples were processed within 1 h, centrifuged at 300 g to remove cells, aliquoted, and 
stored at - 80°C until use. The CSF samples were prepared as described previously [15]: the 
proteins were precipitated with cold methanol, and then the supernatant was evaporated 
under a gentle stream of nitrogen. The derivatization was carried out with methoxyamine 
and MSTFA + 1% TMCS.
GC-MS-FID Analysis
The samples (1 ml) were applied by splitless injection with a programmable Agilent 
CTC PAL multipurpose sampler (Agilent, Atlanta, GA, USA) into an Agilent 7890A 
GC (Agilent, Palo Alto, CA, USA). The chromatograph was equipped with a single HP-
5-MS column (30 m, 0.25 mm ID, 0.25 mm film thickness) and a column flow splitter 




simultaneous acquisition with MS and FID detectors. For sample injection, a septumless 
programmed temperature vaporizing (PTV) injector was used. For each analysis, the 
purge time of the PTV injector was set to 60 s at a purge flow rate of 20 ml/min and an 
equilibration time of 1 min. Helium was used as carrier gas at a constant flow rate of 1 ml/
min through the column. 
For the underivatized compounds, the PTV worked with the following temperature 
program: 60°C held for 0.1 min, and then the temperature was increased to 250°C at a 
rate of 500°C/min. The column temperature was first kept at 40°C for 0.1 min and then 
raised to 280°C at 30°C/min and held for 10 min. For the biological samples, the following 
temperature program was used: 90°C held for 0.1 min, followed by the temperature increase 
to 250°C at 500°C/min. The column temperature was first kept at 70°C for 5 min and then 
raised to 280°C at 5°C/min and held for 10 min. 
The FID was operated at 300°C; hydrogen and air flows were set at 40 ml/min and 
370 ml/min, respectively. The transfer line to the mass spectrometer was kept at 300°C. In 
the AP chemical ionization (APCI) source operating in positive mode, temperature and flow 
rate of the dry gas (nitrogen) were 300°C and 2.00 l/min, respectively. The APCI vaporizer 
temperature was 300°C; the pressure of the nebulizer gas (nitrogen) was set to 3.5 Bar, and 
the voltage of the corona discharge needle was + 4000 nA. Capillary voltage was set to –2000 
V and the end-plate offset to –500 V. The maXis (Bruker Daltonics, Bremen, Germany), 
an orthogonal-accelerated TOF-MS, was used as a MS detector. The polarity of the APCI 
interface and all of the parameters of the TOF-MS detector were optimized with infusion of 
reserpine. Spectra were acquired in scan mode from mass-to-charge ratio (m/z) 100 to m/z 
1000 with 1Hertz (Hz) frequency. External calibration was Performed using a tune mix.
The linear dynamic range for the mix of six underivatized compounds was estimated 
for a concentration range from 0.05 to 10,000 mM. For the standard mix, a concentration 
range, 0.5–50 mM was used. The two calibration lines (APCI-TOF and FID) were used for 
calculation of limit of detection (LOD) and limit of quantification (LOQ; Tables 1 and 2 
in Supplementary Data); these were calculated on the basis of a signal-to-noise ratio of 3 for 
LOD and 10 for LOQ. The background noise was estimated from the peak baseline close 
to the analyte peak. Each calibration point is the result of three independent injections. The 
intra– and inter–day repeatability test was performed using standard mix as a reference. 
Results of the test were expressed as relative SD (RSD). Four independent injections were 
carried out at 25 mM concentration level. The interday repeatability was calculated after 24 
and 48 h. The accurate mass data of the molecular ions were processed with DataAnalysis 
4.0 software (Bruker Daltonics). A list of possible elemental formulas was generated by 
using the SmartFormula module of the DataAnalysis 4.0. It uses a CHNO algorithm, which 
provides standard functionalities, such as minimum/maximum elemental range, electron 
configuration, and ring-plus double bond equivalents, as well as a sophisticated comparison 
of the theoretical with the measured isotope pattern (s value).
RESULTS
To illustrate the complementarity of APCI-MS and FID, we used a mix of six 
organic compounds: 4-chlorophenol, decylamine, methyl caprate, prometryn, aldrin, 
and endosulfan- a. The selection of these compounds is not random; it includes aliphatic 







chromatogram and the base peak chromatogram (BPC) shows (Figure. 1) that the response 
of the MS detector is more compound-dependent than FID. For example, the peaks at 5.3 
and 9.2 min (namely, 4-chlorophenol and aldrin) are quite intense in FID but are nearly 
absent in the BPC generated by the MS detector. 
Figure 1. An example of comparison of the chromatograms recorded with GC-APCI- 
TOF MS (upper) and FID (lower) for six underivatized compounds (100 mM each): 1, 
4-chlorophenol; 2, decylamine; 3, methyl caprate; 4, prometryn; 5, aldrin; 6, endosulfan a.
Table 1. Analytical parameters for underivatized compounds. The gray lines refer to GC-
APCI-TOF MS detector while the white lines are referred to FID  detector. r2, Linear 
regression.










4’Chlorophenol y = 583.54x - 54192 0.9951 50-5000 40.0 133.3 5.27
  y = 0.1639x - 14.011 0.9934 10-5000 8.33 27.78 5.27
Decylamine y = 5317.7x + 96980 0.9933 10-2500 4.29 14.29 5.51
  y = 0.2578x - 27.218 0.9972 25-5000 12.00 40.0 5.50
Methyl Caprate y = 11382x + 1E+06 0.9932 0.5-5000 0.38 1.25 5.84
  y = 0.1682x + 12.262 0.996 0.5-10000 0.59 1.95 5.83
Prometryn y = 55477x + 36030 0.9941 0.05-500 0.06 0.20 8.58
  y = 0.2207x - 1.2977 0.9972 1-1000 0.85 2.82 8.56
Aldrin y = 279.97x - 3776.1 0.9974 5-1000 3.75 12.50 9.07
  y = 0.4799x - 7.9728 0.9960 1-1000 1.58 5.26 9.05
Endosulfan α y = 42543x - 97395 0.9907 0.05-100 0.03 0.09 10.19
  y = 0.2981x - 4.2042 0.9982 5-1000 1.64 5.48 10.16
Table 1 summarizes the analytical parameters for both detectors. Calibration lines, 
LODs, and LOQs were calculated, plotting peak areas as a function of concentration 
[extracted ion chromatograms (EICs) were used for calculations of peak areas in MS]. 




(r2 > 0.991 in all cases). LOD and LOQ are significantly lower for GC–APCI-TOF-MS 
than GC-FID, except for 4-chlorophenol and aldrin. On the other hand, the linear range of 
detection is wider in the case of FID. It is important to mention that the retention times of 
a given compound are almost identical for both detectors (FID and APCI-MS). Thus, using 
this relatively simple example, we have shown that there are substantial differences in the 
response factors and basic analytical parameters (LOD and LOQ) between FID and APCI-
MS detectors. A combination of six organic compounds, even when selected specifically with 
regard to chemical diversity, does not reflect the complexity of biological samples. Besides, 
a large proportion of body fluid metabolites is nonvolatile polar compounds and needs a 
derivatization before GC analysis. Therefore, as a next step, we analyzed a standard mix of 
compounds typically reported as components of body fluids. This mix included compounds 
belonging to different chemical families: amines, amino acids, organic acids, alcohols, and 
xanthines. All chemical species were selected with the specific aim to cover a wide range of 
polarities and MWs, mimicking as closely as possible a real life situation. Figure 2 shows 
typical chromatograms of FID and MS detectors. 
Figure 2. Representative chromatograms of the standard mix (25 mM): APCI-TOF-MS 
(BPC; upper) and FID (lower). Zoom-in: Ile (17.6 min) and Leu (18.2 min).


























Alanine+2TMS+H 12.39 y = 13490x - 45721 0.9686 0.19 0.63 7% 18% 23%
12.40 y = 0.2716x + 2.6521 0.9756 0.24 0.79 5% 14% 14%
Sarcosine+2TMS+H 13.41 y = 6145.7x - 32450 0.9665 3.00 6.47 17% 18% 26%
13.41 y = 0.1097x + 0.0803 0.9537 8.00 26.88 6% 7% 11%
Proline+1TMS+H 14.53 y = 5473.2x - 59848 0.9943 21.58 71.94 16% 16% 21%
14.55 y = 0.2041x - 0.5898 0.9969 18.29 60.98 3% 6% 8%
Valine+2TMS+H 15.83 y = 21344x - 73007 0.9199 0.10 0.33 9% 20% 35%
15.83 y = 0.2403x + 0.0935 0.945 0.78 2.60 1% 3% 5%
Benzoic Acid + 1 TMS+H 16.51 y = 895.29x - 5812.6 0.9998 10.00 33.33 18% 18% 18%
16.50 y = 0.5802x - 1.3997 0.9887 6.66 22.20 2% 6% 5%
Isoleucine+2TMS+H 17.42 y = 23962x - 80202 0.9911 0.34 1.11 19% 24% 25%
17.44 y = 0.3432x - 1.0109 0.9928 5.00 16.60 2% 3% 6%
Leucine+2TMS+H 18.02 y = 30845x - 120980 0.8989 0.13 0.42 26% 17% 16%
18.03 y = 0.6134x - 2.2667 0.9736 1.71 5.71 2% 4% 10%
Glycine+3TMS+H 18.34 y = 3430.7x + 2601.9 0.9747 0.06 0.20 15% 39% 37%
18.34 y = 0.3445x + 1.1661 0.9997 2.70 9.90 14% 30% 27%
Serine+3TMS+H 19.92 y = 34064x - 87840 0.9373 0.07 0.22 12% 13% 19%
19.92 y = 0.4867x - 1.18 0.9279 0.67 2.22 3% 3% 9%
Threonine+3TMS+H 20.62 y = 33259x - 58986 0.9442 0.05 0.16 13% 11% 20%
20.63 y = 0.5272x - 1.0441 0.9241 1.55 5.15 2% 4% 7%
Methionine+2TMS+H 23.75 y = 44225x - 113892 0.9622 0.12 0.40 6% 17% 30%
23.76 y = 0.4499x + 1.2307 0.9839 3.33 11.11 5% 6% 12%
Aspartic acid+3TMS+H 23.92 y = 36461x - 15137 0.9972 0.07 0.24 13% 24% 28%
23.91 y = 0.5083x - 0.7629 0.9784 3.00 10.00 4% 6% 19%
Glutamic acid+3TMS+H 26.20 y = 29834x - 49222 0.9957 0.12 0.38 12% 21% 32%
26.19 y = 0.4277x - 0.5318 0.9933 3.50 11.68 9% 11% 12%
Phenylalanine+2TMS+H 26.26 y = 49218x - 25330 0.9974 0.13 0.44 16% 18% 20%
26.25 y = 0.7029x - 1.1104 0.9924 3.50 11.68 4% 5% 14%
Phenyl-Gly+H 28.06 y = 119260x - 165927 0.9972 0.06 0.18 13% 22% 34%
28.04 y = 0.8171x - 0.7237 0.9956 0.35 1.18 5% 5% 8%
Hyppuric Acid+1TMS+H 30.66 y = 11673x - 26449 0.9918 0.26 0.86 16% 15% 16%
30.64 y = 0.3526x - 0.5933 0.9835 4.77 15.92 6% 13% 11%
Caffeine+H 30.78 y = 114348x - 170144 0.9962 0.23 0.77 5% 10% 9%
30.76 y = 0.3152x + 0.0298 0.9934 1.66 5.55 2% 6% 7%
Theophylline+1TMS+H 32.12 y = 45565x - 62580 0.9952 0.33 1.11 6% 16% 26%




Lysine+4TMS+H 32.53 y = 56140x - 14749 0.9948 0.11 0.36 20% 27% 35%
32.53 y = 0.2126x - 0.3059 0.9875 0.75 2.50 7% 11% 11%
Tyrosine+3TMS+H 32.86 y = 75274x - 46887 0.9963 0.09 0.83 12% 21% 23%
32.86 y = 0.6914x - 0.0326 0.9974 0.59 1.95 6% 8% 6%
4- Methyldopamine 
hydrochlor+3 Si+H 34.40
y = 91126x 
+ 94865 0.9816 0.03 0.10 10% 16% 18%
34.38 y = 0.8979x - 0.4778 0.9992 0.70 2.34 2% 6% 5%
Dopamine hydrochlor+4 
TMS+H 35.53
y = 87513x 
+ 30795 0.9786 0.05 0.18 13% 14% 21%
35.50 y = 1.0494x - 1.0955 0.9945 1.20 4.00 1% 4% 4%
Uric Acid + 4 TMS+ H 36.15 y = 29816x - 35130 0.9984 0.14 0.45 12% 28% 38%
36.15 y = 0.2464x + 0.1531 0.9999 0.94 3.13 6% 10% 34%
5-Hydroxyindole-3-acetic 
+ 3 TMS+ H 37.90
y = 67994x - 
66186 0.995 0.08 0.25 11% 22% 18%
37.91 y = 0.4126x - 0.1815 0.9981 0.58 1.92 4% 5% 13%
Nortriptyline 
hydrochlor+H 38.32
y = 8649.4x 
+ 5316.9 0.995 0.57 1.89 10% 16% 25%
38.26 y = 0.0882x + 0.2164 0.9907 3.33 11.11 8% 27% 39%
Table 2 summarizes analytical data for compounds of the mix (only the most stable 
silylation form of a compound is shown). In agreement with previous data (Table 1), 
retention times for both detectors were found to be identical, and the MS detector showed a 
lower LOD (< 3 mM for MS and < 8 mM for FID), except for proline and benzoic acid (Table 
2). The maximum intraday deviations were 9% for FID and 26% for MS; the maximum 
interday deviations (after 48 h) were 39% for FID and 38% for MS. The RSD after 48 h 
for both detectors indicates degradation in the samples once they had been derivatized. The 
linearity of response was found to be equally good for FID and MS (r2 > 0.95). Even when 
the correlation factor was not ideal (r2 > 0.95), as in the case of valine, serine, and threonine, 
this deviation affects both detectors, which indicates a problem of derivatization, a thorny 
step in the analytical procedure, rather than instability of the detector. The detailed analysis 
of the chromatograms presented in Figure 2 shows how differently both detectors respond to 
certain compounds despite their superficial similarity. For example, Ile and Leu are ‘classical’ 
positional isomers, which have the same atomic composition, number of single and double 
bonds, and consequently, the same masses. The peak areas observed for these compounds 
give a good approximation of the relative detector response. Calculating the peak area ratios 
for FID and MS, we obtain the following numbers: Leu FID/Ile FID = 0.52; Leu MS/
Ile MS = 0.69. Thus, there is a significant difference of the ratios in the Leu/Ile peak areas 
between FID and MS detectors. The effect is also reflected in the angular coefficients of 
the calibration lines: Ile has a higher angular coefficient than Leu (Table 2). This increase 
was found to be larger for FID (+ 44%) than for APCI-TOF (+ 22%). Analysis of the 
compound mass spectra (Figure 3) provides a possible explanation of this effect. Leu and Ile 
are represented by doubly silylated forms. In GC-APCI MS, the parent ion is the dominant 
feature of the spectra, unlike in conventional GC-electronic impact (EI) spectra, where the 
parent is a minor peak or even absent [15]. Main fragments, for Leu as well as for Ile, are 
the result of a loss of neutral groups such as Si(CH3)3OH (m/z 90) or Si(CH3)3OHCO (m/z 
118), leading to formation of m/z 186.1 and m/z 158.1 fragments, respectively. However, 







the methyl group, most probably at position 5; the remaining tertiary carbon at position 3 
stabilizes the positive charge with formation of the m/z 260.1 fragment. Anadditional loss of 
Si(CH3)3OH (m/z 90) leads o the formation of a fragment with m/z 170.1 (Figure 3). 
Figure 3. APCI-TOF spectra for Leucine (upper) and Isoleucine (lower).
Next, we used human CSF to test the applicability of our approach for biological 
material. Figure 4A shows typical BPC and FID chromatograms. With both detectors, very 
complex chromatograms were recorded. A number of molecular features extracted from MS 
data and overview of compounds detected in human CSF with GC-APCI-MS were reported 
elsewhere [15]. At first glance, there is no serious dissimilarity between the chromatograms. 
However, as the representative examples (Figure 4B and C) show, there is a number of 
differences between FID and APCI-MS. Figure 4B shows a few abundant compounds that 
saturate the MS detector. It is a common situation for biological fluids with their enormous 
concentration range. It is evident that realistic quantitative estimation based on MS data 
is impossible. FID, on the contrary, is still far from its saturation point within its linear 
range and therefore, can provide accurate quantitative information. Figure 4C illustrates a 
different situation: in the case of co-eluting or poorly resolved peaks, MS plays an essential 




Figure 4. A) Representative chromatograms of CSF sample: APCI-TOF-MS (BPC upper); 
FID chromatogram (lower). (B) Zoom-in showing examples of peaks saturating the MS 
detector but remaining within linear dynamic range of FID. (C)Zoom-in showing an 
example of EIC used to resolve co–eluting compounds.
DISCUSSIONS
GC-MC at AP has a peculiar history. The first experiments with corona discharges 
have shown the potential of ionization processes at AP [16]. The first instrumental designs 
of GC-APCI/MS were described in the early 1970s, but for a number of reasons, vacuum-
stage instruments took over the market. For decades, GC-APCI/MS remained an exotic 
application.
The combination of GC-MS and GC-FID also is an old idea, with roots going back 
to the 1960s [10, 11]. Horning [2] demonstrated the feasibility of the combination GC-
MS/GC-FID in one of his first reports about APCI-GC. His source design is regularly 







remained unnoticed [17, 18]. One of the common arguments against the routine use of the 
combination of FID and MS is the lack of complementarity [19]. It has been postulated, 
for example, that MS and FID yield a similar chromatogram, and response factors for the 
majority of organic compounds are comparable [19]. This statement, however, is based 
on the comparison of FID signals, which were obtained with classical GC-MS ionization 
techniques: EI and CI. As we have shown here, the difference between APCI-MS and FID 
detectors becomes evident even with a simple mix of six organic compounds. Thus, the 
statement of equal response factors for FID and MS would appear not to be applicable 
to GC-APCI-TOF/MS. However, the difference in response factors and basic analytical 
parameters (LOD and LOQ) is not entirely surprising, considering the different nature of 
the physics of both detectors. Besides, the important question is not whether APCI-MS 
and FID produce different responses but whether those differences are complementary and 
whether the combination of both detectors might thus be beneficial for analysis of complex 
biological samples. 
Our next example, a mix representing the most common body fluid metabolites 
(standard mix), is an attempt to address this question. Our ‘standard mix’ includes 
compounds from several chemical families: amines, amino acids, organic acids, alcohols, and 
xanthines. It is certainly a much more complex sample than the previous one and at a first 
glance, much more diverse. However, the derivatization procedure introduces a common 
bias for all metabolites. In addition, there are not so many heteroatoms, such as, for example, 
chloride. A simple visual inspection of the trace of the chromatogram is not sufficient for 
the comparison of detectors, but the analysis of the basic analytical parameters reveals a 
few interesting features. For example, the MS detector consistently demonstrates lower 
LOD and LOQ values, and the intraday repeatability is significantly better for FID (RSD 
between 1% and 9%, as compared with 6–26% for MS). Moreover, a comparison of the 
data acquired 24 h and 48 h after derivatization indicates that there is a common trend for 
both detectors toward higher RSDs, which is, most probably, a side-effect of derivatization 
instability. Considering that the effects of derivatization on the analytical performance of a 
given method can be circumvented by, for example, an in-line derivatization approach and 
that the MS detector shows better LOD/LOQ, one of the possible preliminary conclusions 
could be that the combination of FID and APCI-MS as parallel detectors is indeed of little 
practical use. However, our analysis of the response of two detectors to such classical positional 
isomers as Leu and Ile proves the opposite, or at least, makes the last statement questionable. 
The difference in Leu/Ile ratios observed with the two detectors is the result of ‘sensitivities’ 
of the detector to different proper ties of compounds: although FID responds mainly to the 
total carbon number, the response of MS is affected by the structural differences between 
the analytes. The tertiary carbon of Ile affects the fragment formation during the in-source/
in-funnel fragmentation process, which leads to the differences in compound spectra and 
eventually changes the response of the detector. On the other hand, FID is also not an ideal 
‘carbon counter’, and its response can be affected by the presence of such heteroatoms as 
chlorine or sulfur. Nevertheless, there are not that many physiologically relevant metabolites 
containing a large number of chlorine atoms, and if there are any, their presence is easily 
detected by unique isotopic patterns.
Our next example was human CSF, which plays a key role in the mechanical and 
immunological protection of the brain, the maintenance of its homeostasis, and metabolism 




areas where a parallel data collection by two detectors (FID and APCI-MS) could be 
useful for the interpretation of GC results. It would thus appear that the combination of 
detectors has at least two possible advantages. Firstly, the wide dynamic range of FID can be 
useful for the exact quantitative estimation of compounds present in biological samples at 
concentrations close to saturation of the MS detector, and those quantitative results are free 
of any ionization and instrumental bias. Secondly, the TOF mass analyzer provides high-
quality structural information, which is essential for the data interpretation in metabolomics 
studies. Moreover, the advantages of APCI mass spectra for structural identification of 
compounds become more evident if we compare them with spectra of traditional GC-MS 
sources, such as EI and CI. The two latter ionization techniques produce spectra, where 
the quasi-molecular ion is low-abundant or even absent. This can be a serious disadvantage 
for the analysis of biological material, where a significant part of compounds is usually 
unknown. With an APCI source, the quasi-molecular ion ([M+H]+) is a dominant one, 
which opens the possibility for structural characterization of unknown compounds using 
the combination of accurate mass and isotopic pattern. In addition, an ionization process 
resulting in the formation of a stable quasi-molecular ion and the technical characteristics 
of modern TOF instruments makes it possible to use such acquisition modes as MS2 or 
multiple reaction monitoring, which are common in LC-MS but seldom used in GC-MS.
Thus, the power of MS as a tool for the structural elucidation of metabolites generally 
needs no additional confirmation, but quantification remains ‘the weakest link’. The 
quantitative response of a mass spectrometer cannot be attributed to a single physical 
phenomenon: it is the product of hyphenation, ionization technique, efficiency of ion optics, 
and the type of mass analyzer. In other words, MS is a selective detector. In routine work, 
dealing with the measurements of known compounds, this selectivity is not a problem: the 
response of the MS detector can be perfectly linear for every single compound. However, 
in explorative studies, where the relative abundance of compounds within the complete 
metabolite profile is as important as the absolute quantity, the mass spectrometer may 
introduce an undesired bias. On the contrary, the quantitative response of the FID detector 
is free from ionization bias and those biases introduced by the type of mass analyzer or the 
instrumental design of a mass spectrometer. Consequently, the FID gives a better overall 
quantitative representation of complex biological samples. As a result, a parallel detection 
for GC-FID, GC-APCI, might offer a quick way to obtain simultaneously the quantitative 
and structural information in metabolic profiling studies.
There are, of course, a few technical issues needed to be resolved to turn parallel 
data acquisition with GC-FID/GC-MS into an efficient method. Those are: the different 
acquisition rates (few Hz for MS and routine 50 Hz for FID), the lack of a proper algorithm 
for data fusion, the development of an optimal strategy for treatment of over-lapping peaks, 
and so on. However, the main purpose of this manuscript was to draw attention to the 
elegant but forgotten idea of the simultaneous use of FID and MS, rather than resolve all of 
the technical problems of this combination. With the reintroduction of APCI sources for GC 
in their modern, user-friendly form, the parallel acquisition of FID and MS chromatograms 
has become a simple instrumental option that requires no additional technical modification 
of the chromatograph. The gain of this dual detector acquisition would appear to be most 
evident for the analysis of complex biological samples. FID is the only detector capable 
of handling concentration ranges typical for body fluids. Its wide dynamic range and 







and the estimation of molar proportions of the different metabolites. MS provides reliable, 
structural information and superior, at least in the case of APCI ionization, sensitivity. 
Taken together, the use of both detectors represents a flexible tool for explorative studies 
and if supported by a powerful data-processing algorithm, would appear to be useful in any 
metabolic profiling study.
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Invented more than three decades ago by Horning, Gas Chromatography Mass 
Spectrometry under atmospheric pressure (GC-APCI-MS) has only recently emerged from 
years of obscurity. However, the general acceptance of GC-APCI-MS is certainly constrained 
by the lack of spectral libraries, which make the traditional GC-MS approaches so powerful. 
Here we present a concept of a GC-APCI-QqToF spectral library. The library is web-based, 
fully searchable and at moment includes spectra of 150 compounds from the most common 
chemical families. The fragmentation pattern of some chemical families is explained and a 
protocol for de novo identification has been provided in order to facilitate the identification 





The article by Linus Pauling on the quantitative analysis of urine vapour [1] is often 
referred to as the first metabolomics publication. The concept outlined in this article resembles 
closely the modern ‘metabolomics’ even though this term was introduced more than twenty 
years later. The work of Horning [2] on analytical methods for the study of steroid hormone 
metabolites is usually quoted in special literature as a seminal work on steroid analysis. Yet, 
to the best of our knowledge, in this manuscript the term ‘profiling’ was introduced for the 
first time as a description of multicomponent analysis of body fluids. Both manuscripts 
are milestones in the development of today’s metabolomics and both exploited the same 
analytical platform – GC. 40 years later, GC still remains the core method of metabolomics 
and its position is hardly threatened by the progress of LC [3-8].
The enduring success of GC can be attributed to many factors, of which the unmatched 
chromatographic resolution and the very fact of being the first separation technique 
used with a mass spectrometer as a detector are probably the most important. Most of 
the commercial GC–MS use vacuum stage ionization sources: Electron Impact (EI) and 
Chemical Ionization (CI). EI is a hard ionization technique, which implies an extensive 
fragmentation of the analytes. The fragmentation patterns are highly reproducible and the 
possibility of using commercial and open source 70eV EI spectral libraries makes GC/EI-MS 
a powerful analytical technique. However, due to the extensive fragmentation the molecular 
ion is seldom present in a spectrum. This could be a disadvantage for the analysis of complex 
spectra populated by structurally similar analytes. Here, CI might offer a solution. Indeed, 
being a softer ionization technique, CI preserves the precursor ions but the results depend 
strongly on the reagent gas or reagent gas pressure used and, consequently, CI spectra are less 
suitable for a library search.
An atmospheric pressure ionization source appears to be a logical next step and 
atmospheric pressure CI (APCI) was pioneered by the same group, which introduced the 
term “profiling” [9]. Developed in the early seventies the GC-APCI was subsequently 
abandoned for almost thirty years till the development of the MS instrumentation created 
an opportunity for its reintroduction. First, McEwen et al. [10] introduced a multipurpose 
source, modifying a commercially available source for LC. Later on, in 2008, Schiewek 
et al. [11] demonstrated the feasibility of GC-MS at atmospheric pressure for APCI and 
atmospheric pressure laser ionization. To date, there have been a number of manuscripts 
published, ranging from technical papers [12-14] to applications such as the analysis of 
pharmaceutical residuals [12], food extracts [15, 16], bio-fluids [17, 18], the metabolome of 
E. coli [19] and sediment phthalates [20].
However, despite a growing number of applications, GC-APCI is still far from being a 
routine technique. One of the factors which seriously downscales the practical value of the 
GC-APCI-MS is the lack of spectral libraries such as available for EI and CI sources (e.g. NIST, 
ADMIS, GOLM) [21, 22]. Here we present the first attempt to create a spectral library for 
GC-APCI-quadrupole-quadrupole (Qq) ToF keeping in mind metabolic profiling of body 
fluids as a prime application. To this end, we have selected a set of compounds belonging 
to those chemical families which are most relevant for the analysis of the biological fluids 
and/or food specimens, and have created a library of reference MS and MS/MS spectra. 
Moreover, anticipating the well-known problem of ‘unknown’ compounds we also provide 
the guidelines for de novo identification.







we have presented our library as a publicly available database resource [101].
MATERIALS AND METHODS
Chemicals
All chemicals at analytical grade were purchased from Sigma or Fluka (Zwijndrecht, 
Netherlands). N-methyl-N-trimethylsilyltrifluoroacetamide with 1% trimethylchlorosilane 
(MSTFA + 1% TMCS) and N,O - Bis(trimethylsilyl) trifluoroacetamide with 1% 
trimethylchlorosilane (BSTFA + 1% TMCS) were applied as derivatization reagents (Pierce; 
Rockford. IL. USA); they were used from freshly opened 1 ml bottles. Methoxyamine 
hydrochloride and the mixes of saturated alkanes (C7-C30 and C7-C40) were purchased 
from Supelco (Zwijndrecht, Netherlands). APCI tune mix (containing purine, 
hexamethoxyphosphazine, hexakis(2,2-difluoroethoxy)phosphazine and hexakis(1H, 1H, 
3H-tetrafluoropropoxy)phosphazine) and pyridine (99%. ultra-pure GC grade) were 
acquired from Fluka. 
Derivatization
All compounds (with exception of some thermo labile ones such as histidine, guanine 
and arginine) were derivatized on-line with a double step silylation. The standards were 
prepared from the stock solutions to obtain a final concentration of 10, 25 or 50 ng/ml 
(depending on the molar response of the compound).
First, 40 ml of a methoxyamine solution (20 mg/ml in pyridine) was added to the dried 
standards and this was then incubated for 40 min at 40 °C; then 50 ml of MSTFA was added 
and incubated at 40 °C for 30 minutes.
For thermolabile compounds, the methoxyamination step was carried out at room 
temperature for 16 h with further addition of 50 ml of MSTFA, and an incubation step at 
room temperature for 1 h.
The flavonoids require no methoxyamination, consequently this step was omitted for 
these compounds. The derivatization was performed with the sole addition 40 ml of pyridine 
and 50 ml of BSTFA and further incubation at 60 °C for 1 h.
To all the compounds, 10 ml of hydrocarbons solution C7-30 or C7-40 were added to 
reach a final concentration of 25 mg/mg.
GC-APCI-MS-Flame ionization detector analysis
The samples (1 ml) were applied by splitless injection with a programmable MultiPurpose 
Sampler MPS2 (Gerstel, Mülheim an der Ruhr, Germany) into an Agilent 7890A GC 
(Agilent. Palo Alto. USA) equipped with one single column (HP-5-MS column 30 m. 0.25 
mm ID. 0.25 mm film thickness) and two detectors running in parallel; a column flow 
splitter is required with deactivated capillaries (0.6 m. 0.25 mm ID. 0 mm film thickness) 
which allows the simultaneous acquisition with both MS and FID detectors (Figure 1). For 
sample injection a septumless PTV injector was used. For each analysis the purge time of the 
PTV injector was set to 60s at a purge flow rate of 20 ml/min and an equilibration time of 1 
min. Helium was used as carrier gas at a constant flow rate of 1 ml/min through the column.
The hydrocarbons solution C7-C30 was spiked to the compounds at a concentration of 




10 ºC/min till 310 ºC held for 2 minutes.
The compounds requiring the addition of the hydrocarbons solution C7-C40, because 
of their late elution, at a concentration of 25 mg/mg were injected with the following 
temperature program: 40 ºC held for 1 minute, 7 ºC/min till 310 ºC held for 15 minutes.
The transfer line to the mass spectrometer was kept at 300 ºC. The APCI source was 
operated in positive mode. The temperature and the flow rate of the dry gas (nitrogen) 
were 300°C and 2.00 l/min. respectively. The APCI vaporizer temperature was 300 °C; 
the pressure of the nebulizer gas (nitrogen) was set to 3.5 bar and the voltage of the corona 
discharge needle was +2000 nA. Capillary voltage was set to -1000V and the end-plate offset 
to -1000 V. The source and detector parameters have been set in order to achieve a minimal 
resolution of 40000.
A maXis 4G (Bruker Daltonics, Bremen, Germany), an orthogonal-accelerated Qq-
ToF mass spectrometer, was used as mass analyzer. The spectra were acquired in a mass range 
from m/z 100 to m/z 1000 with 1 Hz acquisition rate. Before each chromatographic run, a 
tune mix solution was used as external calibrant and injected in Flow Injection mode.
MS/MS experiments were carried out selecting the precursor ion and applying a 
different collision energy for each analyte to achieve the best possible fragmentation.
The FID flows and temperature were set as follows: front detector 300 °C, hydrogen 
flow: 40 ml/min and air flow: 370 ml/min. This detector was used for the calculation of the 
Kovats’ indices, embedded database information for each compound, relative to the specific 
column in use. For the calculation, the equation relative to the temperature programmed 
chromatography was applied [23].
Figure 1. The setup that enables the use of two detectors (flame ionization detection and 
atmospheric pressure chemical ionization–quadrupolequadrupole-ToF) in parallel, the flow 
is split at the end. APCI–Qq-ToF: Atmospheric pressure chemical ionization–quadrupole-








Sera samples from healthy females volunteers were combined into one pool. The 
samples were prepared according to a reference method with minor modifications [24]. 
Briefly, 50 µl of serum was extracted with a 450 µl solution of methanol and water (8:1 v/v). 
The supernatant was dried and reconstituted with 30 µl of methoxyamine in pyridine (20 
mg/ml) and then incubated for 1 hour at 40 ºC. Subsequently we added 30 µl of MSTFA 
and incubated at 40 ºC for 30 minutes.
Library management
The GC-APCI–MS metabolite database is designed to be freely accessible for the public 
over the internet [101]. It is built exclusively from open source software, or software that will 
soon enter the open domain. Debian GNU/Linux 6.0.1 is used as operating system running 
an Apache web server (version 5.3.3) with PHP 5.2 as scripting language for retrieving the 
information from a MySQL (version 5.1.49-3) database. 
The architecture of the database consists of several tables containing the information 
about the metabolite, MS spectra and MS2 spectra.
The metabolite database is accessible through a website, facilitating several general search 
options such as metabolite name, molecular formula or KEGG number. Moreover, a specific 
MS spectra search is also allowed using the measured m/z value with a set mass tolerance. 
The results are returned sorted by m/z error. As an extra option, the search can be expanded 
to seek MS fragments. The users can search for MS2 spectra entering the fragments and their 
relative intensities with the option to take the precursor ion into account. In addition, for 
each compound the retention indices calculated for the used column are provided.
For future contributors an XML structure is being developed for the upload of data 
into the data base. 
RESULTS AND DISCUSSIONS
Spectra interpretation
An important advantage of soft ionisation techniques such as APCI is the preserved 
signal of a precursor ion. Consequently, a combination of soft ionisation and modern high 
resolution ToF instruments creates a perfect platform for the analysis of highly complex 
samples, for instance body fluids, food specimens or even sediment samples. The last 
group has been addressed by David et al. in their report on the analysis of high molecular 
weight phthalates [20]. The parent ion is usually present as protonated species (for positive 
ionization mode). This fact has been carefully investigated by Portolés et al., who analyzed 
the ionization process of a large selection of pesticides and reported that for the 90% of 
the analysed compounds the prominent ionized species was the [M+H]+ [25]. However, as 
Bristow et al. have shown one should not exclude a possibility of odd-electron ions formation 
[12].
In the Table 1 we have listed the common losses we observed in the MS or MSn spectra. 
Some of them are internal molecule fragments; others are related to the presence of the 
derivatization reagent. Some losses (CH3, O, CO) are rather nonspecific, other, however, 




Da) is characteristic for the hydroxyl group – the most reactive towards silylation functional 
group. The consecutive losses of TMSOH give us an indication of the number of OH groups 
in the molecules: representative examples of this phenomenon are the alcohol sugars, such 
as mannitol or sorbitol. 
The loss of 118.0450 Da is characteristic for the carboxylic groups. The presence of an 
amino group can be corroborated by the release of the TMS group with theoretical mass of 
72.0395 Da. Occasionally, we observe a radical molecular ion M˙+ with the consequent loss 
of TMSO (89.0423 Da) and additional fragments related to the TMS group with theoretical 
mass of 73.0474 or 74.0551 Da, depending on the stability of the molecule.
Table 1. Common losses.




























C3H9SiOH + CO [TMSOH+CO] 118.0450
The compounds most commonly detected in body fluids represent the core of our 
selection. Hence, we have included in our database amino acids, sugars, organic acids, 
fatty acids, xanthines, etc. Additionally, we have added a selection of flavonoids, phenols 
and carotenoids as compounds frequently encountered in the bioavailability experiments. 
The website interface facilitates several search options, such as name, molecular formula or 
KEGG number. Since the database is GC-oriented, the Kovats’ index of each metabolite is 
stored and searchable. A MS search can be performed with adjustable mass tolerance (default 
0.05). The m/z value of the molecular or protonated ion of a derivatized compound is often 
used as a search parameter. If metabolites have multiple derivatization forms, a separate MS 
spectrum is stored for each of them. The MS spectrum selected in the search is highlighted. 
Furthermore, in order to unequivocally identify the compounds one is interested in, the 







The MS mode includes fragments related to the in-source or in-funnel fragmentation: 
a search option for these fragments (with the same tolerance) is available. The output results 
are sorted by m/z error and they are shown separately. When a result is selected all the 
information and MS spectrum of the metabolite are displayed.
An MS2 search can be performed on multiple fragments with a set mass tolerance 
threshold (default: 0.05) and the molecular/protonated ion information can be included for 
a more accurate search. The output results are sorted by m/z error and the MS2 spectrum 
displays relative intensities of the fragments. If multiple MS2 spectra are given for a metabolite 
the selected MS2 spectrum from the search is highlighted.
Overview of compound classes
Amino acids. The presence of two functional groups with a different reactivity towards 
the silylation reagent is a characteristic feature of amino acids. The carboxylic group is more 
reactive than the amino group: the compounds with lower silylation substitution always 
indicate the presence of the TMS on the hydroxyl group of the molecule and the compounds 
with higher substitution include derivatization of the amino group as well. As a result, for 
most of the amino acid more than one chromatographic peak was observed.
The amino acids spectra always showed the loss of TMSOH (90.0501 Da) and 
TMSOH+CO (118.0450 Da) corresponding to the carboxylic group and the loss of TMS 
(72.0395 Da) corresponding to the amino group. For all detected silylation forms of the 
amino acids their relative Kovats’ indices are included in the database. 
Fatty acids. A [M+H]+ ion corresponding to the derivatized form of the carboxylic group 
was the main feature of the MS- spectrum of fatty acids (Figure 2A). MS2 spectra, however, 
revealed some peculiarities (Figure 2B). In addition to the classical losses of TMSOH at 
m/z 239.2363 and its cluster series with consecutive losses of CH2 (14.0157 Da), we have 
observed two additional fragments from the protonated molecule corresponding to the loss 
of CH4 at m/z 313.2545 and its substitution with a H2O molecule at m/z 331.2650. In 
order to identify the reaction site, we used the deuterated standard of the palmitic acid 
d-31 of which we report the MS and MS/MS spectra in Figure 2C and 2D respectively. 
MS/MS experiments were carried out with an isolation window of 2 Da. The figure 2D 
shows the protonated molecule m/z 360.4827 (C19HD31O2Si
+), the loss of a CH4 group 
at m/z 344.4493 and a substitution with a H2O molecule confirmed by the exact mass of 
18.0106 Da and the isotopic distribution at m/z 362.4596. The data shows no involvement 
of a deuterium atom, which leads to the conclusion that the observed effect is related to the 
silylation group. The exact location of the reaction site might require an experiment with 




Figure 2. MS and MS2 spectra of palmitic acid and palmitic acid d-31. The MS2 spectra of 
(A & B) palmitic acid and (C & D) palmitic acid d-31 show a substitution reaction of CH4 
with a H2O molecule.
In the analysis of unsaturated fatty acids, regardless of the unsaturation factor, we 
could detect the radical fragment corresponding to the TMS backbone after alpha-cleavage 
(C5H11O2Si
·+) with the theoretical m/z 131.0523. Moreover, in both mono and poly 
unsaturated series of C16 and C18, the fragment C10H15
+ with theoretical m/z 135.1168 
indicates the presence of a double bond. Unfortunately, at the moment we cannot provide 
a sound strategy for the location of the position of the double bond. Vrkoslav and Cvacka 
have recently proposed a strategy for the localization of the double bond position for the 
methyl esters of fatty acids using APCI [26]; it remains, however, to be tested whether their 
approach has more universal applicability.
Sugars. The classical derivatization strategy for sugars consists of two steps, namely 
oximation and silylation. During the oximation the keto group is blocked and the formation 
of enolic forms is inhibited, preventing the cyclization. This reduces the possible isomeric 
forms of a single sugar to just a and b anomers of the sugars’ linear form. Hence, all the 
sugars are represented as protonated molecule (molecular mass with the addition of TMS 
groups on the active hydrogens) and the CH3N group on the carboxylic oxygen.
The ratio between the E- and Z- forms is different for aldohexoses (e.g. glucose) or 
ketohexoses (e.g. fructose). Our results are consistent with a previous report by Funcke et 
al.[27] : the E- form is dominating for the aldohexoses and for the ketohexoses the ratio 
between the two forms is almost equal (Figure 3 A and B). In the MS spectra instead (not 
shown here), the main discriminative feature between the two anomers is the ratio between 
the protonated ion at m/z 570 and the ion at m/z 480 corresponding to the fragment [M+H-
TMSOH]+. For the aldohexose glucose the m/z 480 presents almost the same intensity 







the ketohexose fructose, the m/z 480 presents a low abundance or is absent in both of 
the anomers. The ratio of the anomeric forms can be discriminative feature for standards, 
however, in a ‘real life’ situation (with presence of co-elution, low abundance and high 
noise), it provides no unequivocal identification and needs to be correlated to the retention 
indices provided in the database. MS2 spectra also contain signals characteristic for aldo- 
and keto-hexoses. Figure 3 C - F show the representative MS2 spectra of an aldohexose 
(C and E) and a ketohexose (D and F): the spectra are clearly different for the two species 
due to the relative abundance of the specific fragments at m/z 307.1599 (C12H31O3Si3
+) 
and 217.1090 (C9H21O2Si2




Similar fragmentation patterns have previously been described by Medeiros et al. [28]; 
however the authors assigned the effect to the cycle forms, pyrano or furano rings, which 
is not applicable in our case. Another explanation of the fragmentation has been suggested 
by MacLoed et al. [29], who used 13C incorporation experiments to explain the origin of 
the fragment ions. Our data appear to be in agreement with their model implying fragment 
formation from the straight-chain derivatives.
Analysis of the disaccharides provides a good example of the differences between 
reducing (e.g. lactose) and non-reducing sugars (e.g. sucrose). The first differences are 
noticeable in the chromatographic behaviour of the compounds: lactose, for instance, shows 
two peaks corresponding to the two anomers, while sucrose, which has no open chain form, 
is represented by a single peak. Mass spectra of these compounds are apparently different. 
The spectrum of lactose is characterised by presence of [M+H]+ ion at m/z 948.4639, the first 
glucose moiety ion at m/z 570 and the second glucose moiety after the glycosidic break and 
the subsequent loss of a TMSOH group at m/z 361.1665 (Figure 3G). However, in contrast 
to previously published results [30] the intensity of the m/z 538 ion (corresponding to the 
open chain hexose ion after glycosidic break and the loss of a methyl group) was too low to 
be included in the list of the discriminative fragments. A distinct feature of non-reducing 
sugar (sucrose) spectra is a dominant fragment at m/z 361.1688 resulting from cleavage of 





Figure 3.Chromatograms and spectra of sugars. Base peak chromatogram of (A) glucose 
and (B) fructose. (C & E) MS2 of synand anti-forms of glucose. (D & F) MS2 of syn– and 
anti–forms of fructose. (G) MS spectra example of reducing sugar − lactose and (H) MS 
spectra example of nonreducing sugar – sucrose.
The six carbons alcohol sugars do not have oxime forms so the fragmentation resulted 
in subsequential losses of TMSOH giving always at least one of these ions m/z 307.1576 
(C12H31O3Si3
+), 217.1075 (C9H21O2Si2
+) or 205.1075 (C8H21O2Si2
+). 
Organic acids. This group of compounds consists of relatively small molecules and only 
few of them have nitrogen atoms in their structure. Thus, the loss of the silylanol group is 
usually the only constant feature of their spectra. However, for such compounds as benzoic 
or hippuric acid an additional fragment ion C7H5O
·+ (105.0335 Da), corresponding to the 
benzoyl ion stabilized by the aromatic ring, is detected.
Phenols .To date, only the simple phenols, phenolic acids, lignans and some 
flavonoids are included in the database. As far as phenolic acids are concerned, we included 
hydroxycinnamic acid and hydroxybenzoic acid. In the first group, we can mention o-, m- 
and p-coumaric acids, ferulic, sinapic and chlorogenic acids, and so on. The MS pattern 
for this kind of analytes is characterized by a predominant ion signal corresponding to the 
complete silylated form of each compound, although the hydroxycinnamic acid spectra 
always show the loss of CH4 (16.0313 Da) and the loss of TMSOH (90.0501 Da). For 
isomers such as o-, m- and p-coumaric acids the ions observed in the MS spectra are exactly 
the same, although their relative intensities differ. o-Coumaric acid seems to be the less 
stable of the three isomers, showing the highest intensity of the ion resulting from the loss 







confirmed by MS/MS analysis which provides an unequivocal identification of the structural 
isomers. The compounds included in the group of hydroxybenzoic acids are gallic, vanillic, 
protocatechuic, gentisic, 4-hydroxybenzoic and a-, b-, and γ-resorcylic acids. The protonated 
molecule of the fully silylated compounds is still the predominant ion in the MS spectra and 
the fragmentation pattern is characterized by the losses of CH4 and TMSOH. In almost 
all spectra of the hydroxybenzoic acids, it is possible to observe the loss of CO2 (43.9898 
Da) as well. a-, b- , and γ-resorcylic acids show the same fragmentation pattern, however γ 
-resorcylic acid appears to be the least stable and vulnerable to the in-source fragmentation. 
Homovanillic acid is the only compound belonging to this family and it gives a major ion 
that results from the loss of 118.045006 Da (C3H9SiOH + CO).
Of the flavonoids, some flavanols, flavones and flavanones were included. Their spectra 
are characterized by the loss of CH4 and additional fragments related to the TMS group with 
mass 73.0474 or 74.0552 Da, according to the molecule stability. In the case of flavanols 
(catechin and epicatechin) the loss of TMSOH is more commonly observed than for the 
other flavonoids. 
We have also studied the APCI behaviour of hydroxytyrosol and tyrosol, which are 
simple phenols. They are represented by the radical [M + x TMS]+ instead of the protonated 
molecule [M+ x TMS+H]+ and they showed the loss of C3H9SiO. Pinoresinol, which belongs 
to the lignans, showed as the main signal in the MS spectra the loss of 18.010565 (H2O). 
In its MS/MS spectrum, we observe the fragment 209, which is attributable to the stable 
substituted tropylium ion structure. 
Vitamins. Some vitamins suitable for a GC analysis such as nicotinic acid, pantothenic 
acid, pyridoxine, ascorbic acid, etc. were included in our database as well. Their analysis 
revealed that all the compounds showed the complete silylation of their active hydrogen 
and a very high resistance to the in-source fragmentation process. For the four mentioned 
compounds we observed as predominant signal in the MS spectra the protonated molecule 
[M + x TMS+H]+, and in every case we could observe losses of TMSOH, although piridoxine 
proved to be more sensitive to the in-source fragmentation process, since the loss of 90 was 
more easily observed in its spectrum.
De novo identification of unknown compounds 
Currently our library contains APCI-MS, MS2 spectra and Kovats’ indices for 150 
compounds. Thus, this is only the primer of a library, which should then create a framework 
for a further growth. Routine analysis of body fluids will undoubtedly lead to a quick growth 
of the number of entries. One would need, however, a set of rules or a standard procedure to 
be followed in order to make a valid assignment. Below, we outline the procedure currently 
used for the identification of the unknowns.
• Spectra calibration – an external calibration with tune mix is carried out. Additionally, 
an internal calibration using the losses of siloxanes from the column as lock-masses 
could be performed;
• Identification of the common losses (Table 1) to estimate a number of possible 
elemental compositions;
• Calculation of the theoretical elemental compositions, simulation of the isotopic 
distribution and fitting it to the experimental data. Possible candidates can be listed 




• MSn experiments - Match the MSn spectra with the candidates and their empirical 
formulae and finally define the searched compound;
• Validation on analytical standard, if applicable, this step would provide the highest 
confidence for the identification.
An importance of an established routine for the identification of unknown becomes 
evident once we stepping into analysis of the complex biological samples such as biofluids. 
Figure 4 shows a representative chromatogram of a human serum sample. Using a feature 
finding algorithm provided by the MS vendor (Find Molecular Features; Bruker Daltonics) 
we have found 439 molecular features (the solvent segment was excluded). There is no 
algorithm for the conversion of this number to the number of the real metabolites but our 
experience shows that a 50% cut-off could be applied as a rule of the thumb. Even then 
we could expect twice as more metabolites than in a recent overview of the human serum 
metabolome [31]. At the moment our library provides an unequivocal identity only for a 
limited number of the metabolites (Table 2), a fact which once more emphasizes importance 
of a continuous updated library. 
Figure 4. Representative GC-APCI-MS chromatogram of a serum sample and compounds 
identified in the database and listed in Table 2.
Table 2. Compounds identified in serum samples.






 Error (%) **
1 Urea+ 2 TMS + H+ 205.1181 0.6 2.74 1287.5 3.19
2 Orthophosphoric acid + 3 TMS + H+ 315.1028 0.8 2.68 1287.6 0.29
3 Glycine + 3TMS+H+ 292.1584 -0.5 1.63 1316.0 -0.15
4 Citric Acid + 4 TMS + H+ 481.1915 0.9 1.88 1870.3 1.51
5 Syn-Glucose + 5 TMS + MEOX + H+ 570.2917 -0.1 -1.58 1934.2 -0.47
6 Anti-Glucose + 5 TMS + MEOX + H+ 570.2961 -0.7 -1.14 1952.5 -0.17
7 Palmitic acid + 1 TMS + H+ 329.2870 0.1 0.22 2052.00 0.16
8 Myo-Inositol+ 6 TMS + H+ 613.3056 2.2 3.66 2193.6 2.89
9 Linoleic acid + 1 TMS + H+ 353.2876 0.5 1.29 2216.6 -0.06
10 Oleic acid + 1 TMS + H+ 355.3029 -0.2 -0.65 2223.18 0.05
11 Stearic acid + 1 TMS + H+ 357.3183 -0.4 -1.11 2263.0 0.75
12 Cholesterol + TMS + H+ 459.4018 -0.1 -0.2 3195.6 0.07








Here we present the concept of a GC-APCI-QqToF-MS library. The database is web-
based and includes a number of spectra of compounds from the most common chemical 
families (amino acids, sugars, fatty acids, organic acids, phenols, vitamins and so on) [101]. 
All data included in the database were acquired using a modern UHR-ToF instrument, 
which ensures the high quality of the generated MS and MS/MS spectra. The database 
is fully searchable and includes retention indices and all possible silylation forms for a 
given compound. The fragmentation pattern of some chemical families is illustrated and a 
protocol for de novo identification has been provided in order to facilitate the determination 
of unknown compounds. 
FUTURE PERSPECTIVES
Currently our library includes GC-APCI-QqToF-MS, MS2 spectra and Kovats’ 
indices for 150 compounds, which is only a fraction of metabolites one might encounter 
during metabolomics studies. The practical value of the library will certainly improve if it 
includes data obtained with the instruments of other vendors and/or using different mass 
analysers such as for example, triple quadrupole [14]. We are planning to update this library 
continuously extending a range of biological samples used and trying to extend a range of 
the mass analysers for the data acquisition. 
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Urinary tract infection (UTI) is among the most common bacterial infections 
worldwide. As such, it is an interesting model for the application of the modern integrative 
‘- omics’ technologies and metabolomics in particular. This work is part of a bigger project 
which has the aim to provide a comprehensive overview of UTI-induced changes in urine. 
Here we present the first explorative metabolomics study of UTI using a recently described 
GC-APCI-MS platform. This instrumental set up allows the combination of high resolution 
mass spectroscopy with the robustness and dynamic range of an FID detector, and opens 
new possibilities for cross-platform data analysis, especially in combination with NMR and 
LC-MS. Using well-defined clinical cohort, and taking advantage of a multi-level study 
design, a number of molecular discriminators were identified as specific for UTI patients, 





UTI is among the most common bacterial infections worldwide. Clinical presentation 
of UTI is broad: from a mild cystitis to severe pyelonephritis, which can quickly evolve into 
life-threatening conditions such as urosepsis and multiple organ failure [1, 2]. Thus, with a 
positive bacterial urine culture as common denominator, the term ‘urinary tract infection’ 
includes a variety of clinical syndromes, [3]. To study the physiological alterations going 
along with such complex clinical phenomena, modern integrative ‘-omics’ technologies, and 
metabolomics in particular, are ideally suited. Indeed, metabolomics approaches have already 
been applied to analyse urines from UTI patients, but those studies were either a kind of 
proof of principle studies [4, 5] or were dedicated to the development of a metabolomics 
based routine for uropathogen identification [6]. Each of these studies advocated a specific 
technological solution but it is well known that the use of different analytical platforms 
often results in complementary data. Our aim is to create a comprehensive overview of 
UTI-induced changes in the metabolic patterns of patients’ urine by applying several 
explorative methodologies on a carefully matched selection of patients from a multicentre 
prospective observational study of UTI [7]. So far, well-established techniques such as liquid 
chromatography-mass spectrometry (LC-MS) and nuclear magnetic resonance (NMR) were 
used by us [8, 9]
GC-APCI-MS has only recently been included into the toolbox for metabolite analysis. 
The detection at atmospheric pressure rather than with a vacuum stage (e.g chemical 
ionization and electronic impact) has demonstrated its potential in a wide variety of fields 
ranging from pharmaceutical applications [10], to studies of bacterial metabolism [11], food 
[12, 13] and environmental analysis [14]. In this manuscript, we present the results obtained 
with a recently described GC platform equipped with two detectors running in parallel - 
namely an atmospheric pressure chemical ionization source - mass spectrometer (GC-APCI-
MS) and a flame ionization detector (FID). We applied this platform to the investigation of 
changes in metabolic profiles of urinary tract infection (UTI) patients which may assist in 
monitoring the infectious status of the patients.
MATERIALS AND METHODS
Chemicals 
Methanol, pyridine, iso-propanol, toluene (all at analytical grade) and 
urease were purchased from Sigma (Zwijndrecht, the Netherlands). N-methyl-N-
trimethylsilyltrifluoroacetamide with 1% trimethylchlorosilane (MSTFA + 1% TMCS) was 
used as a derivatization reagent (Pierce; Rockford. IL. USA) and taken from freshly opened 
1 ml bottles. Methoxyamine hydrochloride and the mixtures of saturated alkanes (C7-C30 
and C7-C40) were purchased from Supelco (Zwijndrecht, the Netherlands). APCI tune mix 
(containing purine, hexamethoxyphosphazine, hexakis (2,2-difluoroethoxy) phosphazine 
and hexakis (1H,1H,3H-tetrafluoropropoxy)phosphazine) and pyridine (99%. ultra-pure 
GC grade) were acquired from Fluka.
Clinical samples
Urine samples were collected during a prospective observational multicenter cohort 







primary health care centers participated. From January 2004 till November 2008, patients 
who presented with a diagnosis of febrile UTI, were considered for enrolment in the study. 
The study was approved by the local ethics committees and all patients gave written informed 
consent. Inclusion criteria and exclusion criteria have been described in detail elsewhere [15, 
16]. In short, patients of 18 years or older, with fever and presenting at least one symptom 
of UTI (dysuria, increased frequency of urination, perineal pain, flank pain or costovertebral 
tenderness) and a positive nitrite dipstick test or a positive leukocyte esterase dipstick test 
were enrolled. Exclusion criteria were current treatment for urolithiasis or hydronephrosis, 
pregnancy, hemo- or peritoneal dialysis, a history of kidney transplantation or known 
presence of polycystic kidney disease. Details with respect to empiric therapy and follow-up 
are provided elsewhere [7]. Urine samples were collected at enrolment as baseline samples 
(t=0). After three and thirty days (t=30) urine samples of the same patients were collected 
for follow-up. At all the time points, clean midstream-catch urine samples were cultured and 
analyzed using standard microbiological methods. A positive urine culture was defined as 
bacterial growth of over 103 colony-forming units per ml. Within 2 hours after collection 
all samples were stored at -80° C until further analysis.
For the current study, a group of 67 subjects with culture-confirmed bacteria in the 
urine was selected from a database of approximately 700 subjects. Samples from volunteers 
without UTI or symptoms of another infection were taken as controls. Baseline characteristics 
of the samples are presented in the Table 1. The study design includes the control samples 
and samples of UTI patients collected at baseline (t=0 days) as well as patient follow up 
samples collected after the antibiotic treatment (t=30 days).




Age, years, median [IQR] 59[47–70] 68[54–78]
Male 25 (47) 32 (47)
Smoking 8 (1 missing value) 11
Uropathogen (1 missing value)
E.coli 2 48











Urinary tract disorder 13 16
Malignancy 4 10
Renal insufficiency 3 4
Heart failure 8 7
Diabetes mellitus 0 0
Urine dipstick results
Nitrites 4 (5 missing values) 38 (8 missing values)





Urine samples were prepared according to a reference method with minor modifications 
[17]. Briefly, 100 ml of urine were incubated with 20 Units of urease in 100 ml of water for 
45 minutes at 37 ºC to deplete the excess of urea. Protein precipitation was carried out 
by adding 300 ml of cold methanol and by incubating 10 min on ice. After centrifugation 
at 19,600g for 10 min, 100 ml of the supernatant was transferred to a GC/MS vial and 
evaporated to dryness. All the samples were stored at -80 ºC until the moment of the GC 
analysis.
The samples were derivatized online with a double step reaction. Firstly, we added 50 
ml of methoxyamine (20 mg/ml in pyridine) and incubated for 1 hour at 60 ºC. Secondly, 
we added 50 µl of MSTFA and incubated at 60 ºC for 40 minutes. Subsequently, we added 
100 ml of toluene.
Hundred ul of each urine sample were pooled, aliquoted and then used as quality 
control which were prepared with the same protocol.
GC-APCI-MS-FID analysis 
The samples (1 ml) were applied by splitless injection with a programmable 
MultiPurpose Sampler MPS2 (Gerstel, Mülheim an der Ruhr, Germany) into an Agilent 
7890A GC (Agilent. Palo Alto. USA) equipped with one single column (HP-5-MS column 
30 m. 0.25 mm ID. 0.25 mm film thickness) and two detectors running in parallel; a column 
flow splitter with deactivated capillaries (0.6 m. 0.25 mm ID. 0 mm film thickness) allowed 
the simultaneous acquisition with both the MS and FID detector. For sample injection, a 
septumless PTV injector was used. For each analysis the purge time of the PTV injector was 
set to 60s at a purge flow rate of 20 ml/min and an equilibration time of 1 min. Helium was 
used as carrier gas at a constant flow rate of 1 ml/min through the column.
Urine samples were injected with the following temperature program: 70 ºC held for 1 
minute, the temperature increased till 280 ºC at 5.5 ºC/min and held for 10 minutes.
When identification of compounds was required, we spiked derivatized urine samples 
with hydrocarbons solution C7-C40 at 25 mg/ml and they were injected with the following 
temperature program: 70 ºC held for 1 minute, 5.5 ºC/min till 315 ºC held for 15 minutes.
The transfer line to the mass spectrometer was kept at 300 ºC. The APCI source was 
operated in positive mode. The temperature and the flow rate of the dry gas (nitrogen) 
were 300°C and 2.00 l/min, respectively. The APCI vaporizer temperature was 300 °C; 
the pressure of the nebulizer gas (nitrogen) was set to 3.5 bar and the voltage of the corona 
discharge needle was +2000 nA. Capillary voltage was set to -1000V and the end-plate offset 
to -500 V. The source and detector parameters have been set in order to achieve a minimal 
resolution of 40000.
A maXis 4G (Bruker Daltonics, Bremen, Germany), an orthogonal-accelerated Qq-
ToF mass spectrometer, was used as mass analyzer. The spectra were acquired in a mass range 
from m/z 100-1000 at an acquisition rate of 1Hz. Before each chromatographic run, a tune 
mix solution was used as external calibrant and injected in Flow Injection mode.
For compound identifications Auto MS2 experiments were performed. Collision 
energies were the following: m/z 100 at 25 V, m/z 1000 at 50 V. All the m/z values within 
this interval were fragmented with interpolated values of collision energy.
The FID flows and temperature were set as follows: front detector 300 °C, hydrogen 







Kovats’ indices in comparison with the one provided in our publicly available database [18]. 
For the calculation, the equation relative to the temperature programmed chromatography 
was applied [19].
Statistical analysis
The GC-MS data files were exported as mzXML files. The peak picking was performed 
using XCMS package (The Scripps Research Institute, La Jolla, USA) using the default 
settings except for the following parameter: prefilter=c(2,1000), scan range = c(300, 2920), 
noise level =500, band width=15, m/z width=0.05, minimal sample=41, minimal fraction=1 
[20].
The generated data matrix was imported to the SIMCA-P 13.0 software package 
(Umetrics, Umeå, Sweden). The data were mean centered, unit variance-scaled and Log 
transformed prior to the statistical analysis. The validity and the degree of overfitting of the 
PLS-DA models were checked using a 200 permutations test.
To identify metabolites of interest, rational chemical formulas were generated based on 
internally calibrated monoisotopic masses within 2 mDa mass error, using the SmartFormula 
tool within the DataAnalysis software package (Bruker Daltonics).
RESULTS
GC-APCI-MS is a relatively recent addition to the analytical toolbox for metabolomics 
investigations. Despite the growing number of publications showing the feasibility of this 
new technique, there are no reports demonstrating how it performs in exploratory studies. 
Thus, as a first step of the data analysis, we performed Principal Component Analysis (PCA) 
on the entire data set which included clinical samples and quality control samples (197 
samples in total). The PCA score plot revealed a trend in the first principle component; 
we were not able to assign this effect to known sources of the analytical variability such as 
the acquisition block, the order of injection or the influence of the column. However, the 
PCA model built on clinical samples only (Figure 1) resembled the pattern known from 
our previous work on the same set of samples [8, 9]. Thus, we may conclude that our data 
described UTI related changes in the metabolic composition of the urine adequately, despite 
the unknown trend influencing the first principal component of the PCA model.
In Figure 1 (A and B), the PCA analysis of the 156 clinical samples, including the 
controls, the baseline samples (UTI patients t=0 days) and the follow-up samples (UTI 
patients t=30 days), is shown. Although the first principal component is representing the 
main axis of the variance, a trend separating the UTI-free and UTI-subjects was identified 
along the second and the third components. 
In the next step, we focused on the analysis of the baseline (UTI patients t=0 days) 
and control samples. A PCA analysis of 116 samples (Figure 2A) showed a weak trend in 
the clustering of the UTI samples (t=0 days) versus the controls. Subsequently, a two-class 
PLS-DA model built on the same set of samples demonstrated a rather low predictive power 




Figure 1. Clinical samples PCA model coloured by infectious status. The first and the second 
components display a major trend which cover more than 30% of the total variability (A). 
However, the second and the third component show a tendency in the cluster of the controls 
and UTI patients t=30 days against UTI patients t=0 day (B). R2X(cum)=0.642.
Figure 2. Baseline sample scatter plot, Controls versus UTI patients. A) PCA: 
R2X(cum)=0.622. B) Cross-validated PLS-DA: R2X(cum)=0.383, R2Y(cum)=0.444, 
Q2(cum)=0.265. The low statistical values express a poor separation of the controls against 







Next, we took advantage of the longitudinal study design and built a two-class PLS-DA 
model using the time of the samples collection as class ID (t=0 and t=30 days). In figure 3 
the PCA and PLS-DA models built on the longitudinal part of the dataset are depicted. As a 
result, the quality of the statistical models has clearly improved, displaying higher values for 
both the goodness of fit and goodness of prediction (Figure 3B).
Figure 3. UTI patients scatter plot, UTI patients t=0 days versus UTI subjects t=30 days. A) 
PCA: R2X(cum)=0.604,. B) Cross-validated PLS-DA: R2X(cum)=0.389, R2Y(cum)=0.78, 
Q2(cum)=0.422. The improved values of the statistical models describe more adequately the 
infectious status displaying a clear trend of the UTI patients t=0 days against UTI patients 
t=30days.
To get an insight into the metabolic differences between the day of enrolment (t=0 days) 
and after the recovery (t=30 days), we focused on m/z signals with significant VIP values (> 
1.5) within the PLS-DA model. As such, we selected 68 m/z values which could be grouped 
into 11 chromatographic peaks, when sorted by retention time. For the identification of the 
underlying compounds, we used two strategies. First, we checked whether the metabolites 
were present in our publicly available in-house developed database (http://metams.lumc.
nl), using the spectra (MS and MS2 spectra were compared by visual inspection) and the 
retention index estimated using FID (calculated errors for retention indices were kept below 
1.5%). If the compounds were not present in the library, de novo identification, according to 
the protocol provided elsewhere [18], was applied. Table 2 summarizes the results of these 
analyses. 
Two of the features with VIP value > 1.5 were identified as hydroxyhippuric acid. 
Hydroxyhippuric acid has three isomeric forms, 2-, 3- and 4-hydroxyhippuric acid. 
2-Hydroxyhippuric acid is one of the main metabolites of salicylic acid; however, the use 
of aspirin was not reported in the metadata. Therefore, we reasoned that the observed 




glucuronide, one of the major metabolites of paracetamol; however, in comparison to our 
previous studies (LC-MS and NMR), its influence on the model appears to be less strong. 
Table 2. Identification of the features with VIP values > 1.5











Citric Acid (tetra-TMS) 481.1929 0.29 In-house library
Myo-Inosiol (hexa-TMS) 613.3081 1.3 In-house library
3-Hydroxyhippuric Acid (di-TMS) 340.1391 De novo
4-Hydroxyhippuric acid (di-TMS) 340.1391 De novo
Acetaminophen Glucuronide (penta-TMS) 688.3006 De novo
One of special features of GC-MS at atmospheric pressure is the possibility to use a 
Flame Ionization Detector (FID) simultaneously with MS [21]. The FID is an extremely 
simple detector: burning of the carbon compounds in the hydrogen flame results in the 
production of ions and the detector’s response is roughly proportional to the number of 
carbon atoms [22]. Due to an enormous dynamic range and a predictable response, the FID 
is often the detector of choice for quantitative analysis. Even though quantitative analysis 
was not part of this study, we sought to compare the FID responses with the quantitative 
data obtained for a number of metabolites in our previous study [9]. Figure 4 presents 
an example of such comparison for hippuric acid, a compound detected in both NMR 
and GC-MS studies. The response of the FID detector, expressed as area under the curve, 
correlates with the NMR data, while the correlation of the MS and NMR data was poor 
(data not shown). 
Figure 4. Hippuric acid response. The FID response, expressed as area under the curve, 
correlates with the quantitative NMR data. The deviations from the linearity might be 
explained with the presence of co-eluting peaks such as citric acid, which is present in high 








Here we present the first GC-APCI-MS-based explorative study of urines from UTI-
patients. This work is part of a larger study in which we aim to create a comprehensive 
overview of UTI-induced changes in the metabolic patterns within the urine of these 
patients. The sample set used for the current study has previously been characterized with 
two other analytical platforms, namely NMR and LC-MS. Those two studies provided us 
with complementary pictures of the metabolic changes related to the UTI and the recovery 
process. NMR has revealed a set of metabolites indicative for the degree of the infection, 
while the LC-MS study resulted in the identification of O-glycosylated fragments of 
fibrinogen alpha chain as possible morbidity markers.
In comparison to the NMR and LC-MS studies, the GC-APCI-MS data set demonstrated 
some special features. Firstly, the influence of the exogenous compounds such as paracetamol 
metabolites, on the data matrix was much less pronounced than in both previous reports. 
Secondly, this data set contained a trend in the first principle component which we were 
not able to assign to known sources of analytical variability such as the acquisition block, 
the order of injection or the influence of the column. However, considering the number of 
principal components (in total 17) explaining the model and the fact that our PCA model 
on the GC-APCI-MS dataset closely resembled the pattern observed in our previous work, 
we attempted to explore the biologically relevant variance. To this end, we concentrated on 
the statistically strongest model, using the time of the samples collection as class ID (t=0 and 
t=30 days). In doing so, we observed 68 features with VIP values above 1.5, grouped into 11 
chromatographic peaks. As Table 2 shows, we were able to provide structural identity only to 
a part of the classifiers but those which were identified are consistent with previous reports 
on UTI [9]. However, at the moment it is difficult to determine the degree of the overlap 
between GC-APCI-MS profiling and the other platforms used. 
The features with the highest VIP values were identified as isomers of hydroxyhippuric 
acid - putatively 3- and 4- hydroxyhippuric acid. 3- and 4-Hydroxyhippuric acid are acyl 
glycines and usually seen as the products of microbial metabolism. However, hydroxyhippuric 
acid and especially 4- hydroxyhippuric acid is also implicated in the development of kidney 
failure [23] and was even proposed as a marker for monitoring the efficacy of dialysis [24]. 
More recently, 4-hydroxyhippuric acid has been indicated as a potent human erythrocytic 
Ca2+- ATPase inhibitor in end-stage renal failure patients. [25]. With pyelonephritis being 
one of the frequent forms of complicated UTI, a link between hydroxyhippuric acid and 
kidney function provides an interesting topic for further study. 
Citrate is another ‘simple’ metabolite with a complex functional network. Citrate 
is often solely considered as one of the intermediates of the TCA cycle. However, as a 
constituent of body fluids, it plays a different but equally important role in the regulation 
of homeostasis. The three carboxylic groups of a citrate molecule may form complexes with 
metal ions and/or other divalent cations; as such, citrate has been implicated in the control 
of renal stone formation by forming soluble complexes with calcium [26]. Since many 
years, citrate excretion in urine is used for the assessment of the renal function: for example, 
reduction of urinary citrate, which we observed for UTI patients at t=0 days, is an alerting 
signal for pathological changes in the renal metabolism. There are multiple reports showing 
the decrease of the urinary citrate in nephrolithiasis [27], glomerulonephritis [28] and more 
recently in infectious diseases [9, 29]. Thus, the results obtained with our GC-APCI-MS 




Even a brief overview of the metabolomics literature shows that the presence of 
inositol in urine, in its several isomeric forms, is an established fact. The picture seems a 
bit unclear, however, when it comes to the functional implication of urinary excretion of 
those compounds. A fraction of myo-inositol has a dietary origin, either as free inositol, 
phytic acid or inositol-containing phospholipids. Another and larger part is related to renal 
biosynthesis. Under normal conditions, up to 98% of myo-inositol is reabsorbed in the 
renal tubules. Consequently, increased concentrations of myo-inositol are considered as an 
indication of ongoing pathological changes in the renal system: increased concentrations of 
urinary myo-inositol were reported for patients with diabetes [30-32] and renal failure [33]. 
The increased levels of the myo-inositol observed in our study could also be interpreted as a 
consensus of acute pyelophritis.
In conclusion, this profiling platform combines high resolution mass spectroscopy data 
with the robustness and the wide dynamic range of the FID detector but also opens new 
possibilities for cross-platform data analysis, particularly in combination with such a well-
established metabolomics platform as NMR.
CONCLUSION
Here, to the best of our knowledge, we have presented the first application of an 
explorative metabolomics study on a GC-APCI-MS platform. As part of a bigger project 
aimed at the comprehensive overview of UTI-induced changes in urine, this study points 
some physiological marker of the febrile UTI status. Although obviously no firm biological 
conclusions can yet be drawn, this study nevertheless has provided findings which may 
further on contribute to the understanding of the physiological mechanisms underlying the 
progression of UTI.
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 Metabolomics is a technology driven discipline but unlike genomics or even proteomics 
there is not a single analytical platform which enables a comprehensive overview of the 
entire metabolic space. One can always find an argument in favor of (or against) a particular 
analytical solution but, regardless of the argumentation, any analytical technology provides 
only a slice of the metabolome. Thus, with this thesis one particular clinical problem has 
been studied, namely urinary tract infection, using several analytical approaches: this 
included well-established methods such as NMR and LC-MS, as well as a novel GC-APCI-
MS platform. Each platform was used for the investigation of the urinary metabolite profile 
of a carefully matched selection of UTI patients and controls.
In chapter two we used a non-targeted profiling by NMR showing the number of 
metabolites such as acetate, lactate and trimethylamine which are correlated with number 
of bacteria (CFU/ml). However, more interesting results using the NMR technique were 
obtained when the longitudinal axis of the study design was used rather than the simpler 
case/control approach. A few compounds such as p-aminohippuric acid and scyllo-inositol 
were proposed as the markers of the recovery process. Those compounds could reflect the 
renal plasma flow and glomerular filtration efficiency and thus of the kidneys’ functionality.
The NMR study in chapter two has once more demonstrated that an exploratory 
approach has some advantages of over the targeted. A non-targeted study gives the 
opportunity to discover the unknown associations in the data and uses, to the full extend, the 
multivariate nature on NMR and mass spectrometric data sets. For instance, the exploratory 
study performed with LC-MS (chapter 3) demonstrated a new and unexpected finding: 
using a combination of unsupervised and supervised multivariate modeling we discovered 
a fibrinogen alpha 1-chain peptide as potential morbidity marker. The release of proteolytic 
fragments of fibrinogen has earlier been reported in response to an infection or involved in 
cases of kidney disease is not exciting itself and is not new [1]. Recently, antimicrobial activity 
has also been attributed to the peptide released from fibrinogen [2]. The novelty of the 
findings reported here lies in the structure of the fibrinogen that carries a glycosylation which 
changes our understanding of the fibrinogen structure that was considered glycosylation free 
in this part of its chain. Certainly this observation needs further validation in a larger and 
more heterogeneous cohort of samples; nevertheless the increased release of the glycosylated 
fibrinogen alpha chain in febrile UTI patients has shown a reasonably good predictive value.
NMR and LC-MS are the most frequently used techniques in metabolomics; both can 
rely on broad range of data processing software solutions (commercial and open source), 
spectral libraries and data bases. However, a quest for novel analytical solutions is still ongoing 
since none of the existing methods matches chemical diversity and wide concentration range 
of the metabolites comprising human metabolome. At first glance GC-MS hardly can be 
presented as a novel method, this method was used for the investigation of metabolic profiles 
in body fluids long before the term metabolomics was introduced [3]. The modernization 
of such a technique flows into a variety of platforms which find applications in any type 
of metabolic profiling. Nonetheless, GC-MS under atmospheric pressure (GC-PCI-MS) is 
certainly a novel (for metabolomics) method.
Indeed, for GC-APCI-MS an extensive evaluation of the analytical performance is still 
needed. As indicated in the chapters 4 and 5, the combination of gas chromatography and 
mass spectrometry under atmospheric pressure is not entirely a new concept but rather a 
re-introduction of an old idea in a modern, user-friendly form. The value of this method for 




of mass spectrometrer as detector with an addition, simple but nonetheless powerful detector 
- FID. Chapter 4 describes the detailed analytical evaluation of this idea and demonstrates the 
applicability of this platform to the study of the metabolite profile in biological samples. The 
dual detector set-up may be very convenient for the analysis of complex biological samples 
such as for example body fluids. On the one hand, GC-APCI-TOF-MS offers high-quality 
data that are essential for the structural assignment of the metabolites. Using the APCI 
source, in fact, the protonated molecule ([M+H]+) is the dominant feature in the spectra, 
that provides the possibility for structural characterization of unknown compounds using 
the combination of the accurate mass, the isotopic pattern and the MSn experiments. On 
the other hand, in explorative studies, the relative abundance of the observed compounds in 
the metabolic space covers a wide dynamic range which the mass spectrometer cannot cover. 
In this respect, FID is one of the few detectors capable of handling such wide concentration 
ranges and it can provide more reliable quantitative data.
Despite the growing number of studies which demonstrate its value, GC-APCI-MS 
is not yet considered as a routine platform. There are a few reasons for this but the lack of 
a spectral library certainly limits the practical value of GC-APCI-MS for metabolomics 
studies. The development of such library, as described in the chapter 5 of this thesis, might 
facilitate the identification of metabolites in body fluids. The spectral library presented here 
includes the majority of the compounds most commonly encountered in the analysis of 
body fluids, such as amino acids, sugars, organic acids and so on. The web-based library 
is fully searchable and publicly available. As any web-based application, it is planned to 
continuously update our database and the first practical applications are included in the 
chapters 5 and 6.
Finally, the application of GC-APCI-MS platform proved to be successful for the 
explorative study of the urinary metabolites in the context of UTI (Chapter 6). In this work, 
uremic solutes such as myo-inositol and citrate were found to play a role in the characterization 
of UTI patients as well as the altered concentration of two isomers of hydroxyhippuric acid, 
which is known as a potent human erythrocytic Ca+2 - ATPase inhibitor in end-stage renal 
disease. This might reflect the link between the tissue invasive process in febrile UTI, such as 
pyelonephritis, and functionality of the kidney. 
The joint effort of these technologies has allowed a comprehensive overview of the 
complex sequence of the physiological events unfolding the process of an infection. The 
analytes detected with different techniques reflect the various aspects of the UTI such as 
the effect of the bacterial growth, the affected renal functionality and also the production of 
aberrant peptides.
In a longer and speculative perspective, this type of markers could potentially be used 
in routine clinical chemistry and for therapy decision making. 
FUTURE PERSPECTIVES
The multiplatform approach, here reported in the UTI context, demonstrate the value 
of metabolomics as general profiling tool in a clinical environment, providing a better insight 
into altered metabolic phenotype and disease pathogenesis.
Despite the explosive growth of the field of metabolomics, ‘clinical metabolomics’ is still 
in its infancy, but with the analytical technologies and the computing power evolving rapidly 








into clinical and epidemiological studies. But can we foresee which analytical solution will 
become ‘the standard’ of metabolomics? If a question “What is the best analytical technique 
for metabolomics?” is going to be asked, no straightforward answer will be possible. The 
chance to find a molecule (or a set of molecules) with high clinical impact depends on the 
ability to efficiently combine the right technology with a meaningful study design. As shown 
for UTI, each analytical platform uncovers a slice of the biology of a certain status and the 
key of the success lies in the formulation of the proper biological question. From that point 
of view, one should choose the proper collection of samples and instrument according to the 
phenomenon of interest. 
This thesis has shown the complexity of the UTI problem demonstrating how the 
metabolic patterns measured with different analytical instrumentation can reflect different 
physiological processes: bacterial infection (NMR), the host response (LC-MS) and the 
physiological status (GC-APCI-MS). Each of this aspect is a valuable point in the extensive 
understanding of the UTI as infectious disease and could be useful during the assessment of 
the disease severity or the decision making.
All this was possible due to the flexibility in the selection of the analytical instrumentation 
and an appropriate study design. From this experience, it is clear that with regard to 
generating markers with a potentially high clinical impact, the key of success does not lay in 
the chosen platform itself but what makes those markers suitable for practical application is 
the right biological question, a study design that describes adequately the phenomenon of 
interest, and the last but not the least practical considerations such as the number of samples 
and the platform robustness.
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Metabolomics is a rapidly evolving post-genomics discipline which focuses on the 
analysis of metabolites. The totality of an organism’s metabolites –the metabolome– is 
considered to be the closest approximation of the phenotype of a given organism. Analysis of 
the metabolome and its changes in the complex transition between health and sickness may 
contribute to our  understanding of human physiology and open new ways for diagnostics. 
However, an implementation of ‘metabolomics thinking’ in clinical research is still in its 
relatively early days. On the other hand metabolomics itself has to adopt to the requirements 
of clinical research. These two elements are essential in the process of convergence between 
clinical and analytical components which should lead to the recognition of metabolomics of 
body fluids as a fully accepted measure in medical research. This thesis represents a further 
step in this direction using a multiplatform metabolomics approach to investigate one of the 
most frequent infectious diseases– urinary tract infection (UTI). 
Chapter 1 shows a detailed overview of the explorative metabolomics studies of human 
infections with the emphasis on metabolic adaptation to an acute or chronic infection. 
The relevant literature has been comprehensively summarized including, for example, 
information on the study design, number of subjects, employed technology and metabolic 
discriminators. Future considerations, such as importance of the time-resolved study designs 
and the embedment of metabolomics in large-scale epidemiological studies are discussed.
This thesis provides an exhaustive exploratory study of the metabolic pattern of patients 
affected by urinary tract infection. UTI is a common infectious disease that encompasses 
a variety of clinical syndromes with a positive bacterial culture as common denominator. 
Here, this complex clinical entity was investigated with a multiplatform approach.
Chapter 2 describes the application of nuclear magnetic resonance (NMR) to the 
study of UTI-induced changes in the urinary profile. Firstly, multivariate data analysis 
adequately described the difference between cases and controls. The models built on the 
classical case/control design correctly predicted the outcome of the recovered patients 
in 86.5 % of the cases. However, this separation was partially biased by the presence of 
paracetamol metabolites in the urine samples. In this respect, more complex data analysis 
approaches provided more relevant information of the infectious status. For instance, pair–
wise analysis of the UTI patients and their follow-up samples revealed a number of classifiers 
with improved statistical significance as well as the regression-based analysis of the relation 
between 1H-NMR data and the bacterial load in urine. The lists of discriminators obtained 
from different models presented some overlap such as acetate, lactate, and trimethylamine, 
which are often associated with bacterial growth, but also showed some unique features such 
as para-aminohippuric acid, a well-established diagnostic marker for glomerular filtration.
Chapter 3 provides an additional perspective to the same set of samples by using another 
well-established technique in metabolomics namely liquid chromatography coupled with 
mass spectrometry (LC-MS). In this case, the combination of unsupervised and supervised 
multivariate modeling indicated an altered concentration of O-glycosylated proteolytic 
fragments of the human fibrinogen alpha 1–chain in UTI patients. The unequivocal 
identification of this peptide required MS2 and MS3 experiments on two different platforms 
–namely ESI-UHR-Qq-ToF and ESI-ion trap MS–, manual spectra interpretation for de 
novo sequencing, BLAST searches and, finally, a comparison of the experimental tandem 
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mass spectra with those of custom synthesized candidate peptides. The novelty of these 
findings lies in the observed modification of the existing concept of the fibrinogen structure 
which was considered, to the best of our knowledge, to be free of glycosylation in this part 
of its chain.
As was mentioned above, clinical metabolomics is still in its infancy and as such the 
field is open for new analytical solutions in order to provide markers with high clinical 
impact.
In this thesis, the application of one of the oldest separation techniques, gas 
chromatography (GC), in a renewed and more user friendly role, showed complementary 
results to those obtained with a NMR and LC-MS platform. GC in combination with an 
atmospheric pressure chemical ionization source (APCI) can provide new insight in the 
metabolic profile. This possible value was recognized from the very first day in the seventies 
when the technology was applied to the analysis of urinary organic acids but it was never 
investigated in detail. Moreover, the use of GC-APCI-MS in combination with one of the 
oldest GC detection methods, namely flame ionization (FID), allows a parallel acquisition.
Chapter 4 presents the extensive evaluation of the basic analytical parameters for both 
detectors such as limit of detections, limit of quantification, reproducibility intra– and 
inter– day, and linear dynamic range. As expected, FID appeared to be more robust over 
time, showing lower relative standard deviations while MS demonstrated higher sensitivity, 
reflected in lower limits of detection. The benefits of the dual detection was evident in the 
analysis of complex biological samples where the wide dynamic range and the predictable 
molar response of the FID may offer a quantitative overview of the sample composition. 
On the other hand, APCI–MS provides superior information for structural elucidation. The 
analysis of complex real samples such as cerebrospinal fluid showed that this combination 
represents a powerful tool for explorative studies.
Despite the advantage of such a built platform for explorative studies, real clinical 
applications are still lacking. There several reasons for this but the lack of a spectral library, 
that makes the application of the traditional sources so powerful, is one of them.
Chapter 5 reports the first web-based spectral library for GC-APCI-MS. This library 
is publicly available at http://metams.lumc.nl/ , fully searchable and facilitates many search 
options such as metabolite name, molecular formula and KEGG number. Moreover, a 
specific MS spectrum search is also allowed using the measured m/z value with a set mass 
tolerance. The entries include MS and MS2 spectra, and retention indices calculated with 
the FID detector. At the moment, the library contains the metabolites mostly encountered 
in the analysis of body fluids (amino acids, sugars, fatty acids, vitamins) but, as any web-
tool, it is planned to be continuously updated. Its application was tested in the analysis 
of complex samples (serum). However, in the analysis of biological samples one might 
encounter compounds which are not yet included in the library or unknown compounds. In 
order to facilitate the identification of such molecules, a protocol for de novo identification 
is also provided.
Finally, Chapter 6 describes the first application of GC-APCI-MS in a clinical 
environment to investigate the UTI-induced change in the urinary metabolic profile. The 








up which, on the basis of bacterial culture results, showed no longer sign of infection. The 
previous developed spectral library (Chapter 5) allowed the identification of the molecules 
driving this separation by matching both the spectra and the retention indices. Moreover, 
some of the compounds not present in the database could be identified with the de novo 
protocol. The list of molecular descriptors includes uremic solutes such as myo-inositol 
and citrate but also isomers of hydroxyhippuric acid, which might be descriptors of a 
certain physiological status since their presence has previously been related to the Ca2+–
ATPase inhibitory activity in end–stage renal failure patients. In addition, the robustness 
and dynamic range of the FID detector was used to investigate new possibilities for cross-
platform data analysis, especially in combination with NMR and LC-MS. 
This thesis shows the complexity of the UTI problem and the complementarity of 
different analytical tools which are able to measure different metabolic patterns, reflecting 
diverse physiological processes. Each of the used platforms added a unique perspective to 
the further understanding of the infection process. The assessment of the bacterial growth 
(NMR), of the host response (LC–MS) and of the physiological status (GC-APCI-MS) 





Metabolomics is een snel groeiende post-genomics tak van de wetenschap die zich 
bezighoudt met de analyse van metabolieten. Het totaal aan metabolieten in een organisme, 
het metaboloom, wordt gezien als de meest nauwkeurige representatie van het fenotype. 
De analyse van het metaboloom, en de veranderingen ervan bij de overgang van ‘gezond’ 
naar ‘ziek’, kan een bijdrage leveren aan het beter begrijpen van de humane fysiologie en 
zodoende mogelijk nieuwe diagnostische methoden verschaffen. Echter, de implementatie 
van het denken in termen van metabolomics  in klinische studies is tot nu toe beperkt. 
Omgekeerd zullen metabolomics studies aangepast moeten worden aan de eisen die klinisch 
wetenschappelijk onderzoek met zich meebrengt. Het samengaan van deze klinische en 
analytische aspecten zijn de belangrijkste factoren voor de acceptatie van metabolomics van 
lichaamsvloeistoffen in het medisch onderzoek. Dit proefschrift beoogt aan dit proces een 
bijdrage te leveren door de toepassing van een multi-platform metabolomics benadering bij 
onderzoek aan urineweginfecties, één van de meest voorkomende infectieziekten. 
Hoofdstuk 1 geeft een overzicht van de exploratieve metabolomics studies van humane 
infecties met de nadruk op de metabole veranderingen die gepaard gaan met acute en 
chronische infecties. Er wordt een uitgebreid overzicht gegeven van de relevante literatuur 
met inachtneming van informatie over studie opzet, aantal patiënten, gekozen technologie 
en metabole  veranderingen. Toekomstperspectieven zoals het belang van longitudinale 
studies en de implementatie van metabolomics in grootschalige epidemiologische studies 
worden bediscussieerd. 
Het proefschrift behandelt verder uitgebreide exploratieve analyses van de metabole 
patronen van patiënten met urineweginfecties (UTI). UTI is een veelvoorkomende 
infectieziekte met een verscheidenheid aan klinische verschijnselen met als gemeenschappelijk 
kenmerk een positieve bacteriële kweek. In deze studie is deze complexe klinische entiteit 
onderzocht met een verscheidenheid aan analytische platforms.
In hoofdstuk 2 is UTI onderzocht door middel van NMR (nuclear magnetic 
resonance) analyse van urine met als doel de UTI-geïnduceerde veranderingen in kaart te 
brengen. Multivariate data analyse resulteerde in eerste instantie in een duidelijk onderscheid 
tussen patiënten en controles. Een model gebaseerd op deze eenvoudige patiënt-controle 
studie gaf in 86.5% van de gevallen een correcte voorspelling van de patiënten die hersteld 
waren. Echter, de aanwezigheid van paracetamol speelde hierin een belangrijke rol. Een 
uitgebreidere analyse gaf een meer relevante weergave van de infectiestatus. Een paarsgewijze 
analyse van urines van patiënten zowel tijdens de infectie als ook na herstel gaf een duidelijker 
en significanter onderscheid tussen de verschillende groepen weer. Dit gold ook voor de op 
regressieanalyse gebaseerde beschrijving van de relatie tussen de proton NMR data en de 
hoeveelheid bacteriën in de urine. Sommige metabolieten kwamen in meerdere analyses 
als onderscheidend naar boven, zoals bijvoorbeeld acetaat, lactaat en trimethylamine. Deze 
metabolieten worden vaak geassocieerd met groei van bacteriën. Daarnaast werden er ook 
model specifieke metabolieten aangetoond, zoals bijvoorbeeld para-aminohippurinezuur, 
een algemeen geaccepteerde diagnostisch marker voor glomulaire filtratie.
In hoofdstuk 3 is dezelfde set aan samples geanalyseerd met een reeds algemeen 
geaccepteerde techniek in metabolomics, LC-MS (vloeistofchromatografie gekoppeld 
met massaspectrometrie). Uit deze dataset werd via een combinatie van zowel ‘supervised’ 








O-geglycosyleerd peptide van de alpha-1 keten van fibrinogeen gevonden in urines van 
mensen met UTI. De identificatie van dit peptide werd mogelijk gemaakt door het gebruik 
van MS2 en MS3 experimenten op twee verschillende massaspectrometrisch platforms, ESI-
UHR-Qq-ToF en ESI-ion trap, handmatige interpretatie van de verzamelde spectra en 
sequentie-specifieke zoekopdrachten in databases. Uiteindelijk vond de positieve identificatie 
plaats door middel van het vergelijken van de experimentele fragmentatiespectra met die van 
een, op basis van bovenstaande analyse, gesynthetiseerd peptide. Dit is naar ons inziens de 
eerste keer dat in dit deel van fibrinogeen glycosylering is aangetoond en mede daardoor is 
deze ontdekking zo opvallend.
Zoals boven beschreven is metabolomics een relatief jong vakgebied en dat biedt dus de 
mogelijkheid tot het vinden van nieuwe analytische oplossingen om te komen tot markers 
met een hoge klinische impact.
In dit proefschrift blijkt dat een ‘zeer oude’ scheidingstechniek zoals GC 
(gaschromatografie) in een nieuwe en meer gebruikersvriendelijkere opzet resultaten oplevert 
die complementair zijn aan die van NMR en LC-MS. Gekoppeld aan chemische ionisatie 
onder atmosferische druk (APCI) kan GC nieuwe inzichten geven in het metabole profiel. 
De kracht van deze combinatie werd al in de jaren zeventig onderkend in een studie gericht 
op de analyse van urinezuren, maar is nooit verder in detail onderzocht. Bovendien geeft de 
bijzondere combinatie van GC-APCI-MS en de oudste GC detectie methode, vlamionisatie 
(FID), de mogelijkheid tot parallelle data acquisitie (zie hieronder). 
In hoofdstuk 4 is voor beide detectiemethoden een uitgebreide evaluatie gedaan van 
de analytische parameters zoals gevoeligheid, reproduceerbaarheid (zowel binnen een dag als 
tussen verschillende dagen) en het lineaire dynamische gebied. Zoals verwacht bleek FID in 
de tijd een meer robuuste techniek en gaf als zodanig lagere standaarddeviaties terwijl MS 
gevoeliger was en dus een lagere detectielimiet had. Het voordeel van de combinatie van 
beide detectietechnieken was het meest duidelijk bij de analyse van complexe biologische 
monsters. In deze gevallen geven het hoge dynamische bereik en de voorspelde molaire 
respons van FID de mogelijkheid om een kwantitatief overzicht van de monstersamenstelling 
te geven. Aan de andere kant is APCI-MS essentieel voor de opheldering van de structurele 
kenmerken van de aanwezige componenten. Uit de analyse van een complex monster zoals 
cerebrospinale vloeistof  werd duidelijk dat deze combinatie een krachtige methode is voor 
exploratieve studies.
Ondanks de mogelijkheden van het boven beschreven platform is de echte klinische 
toepassing beperkt . Eén van de redenen hiervoor is het gebrek aan databases met spectra, 
zoals die in het verleden met veel succes zijn toegepast bij andere manieren van ionisatie.
In hoofdstuk 5 wordt de eerste web-based database met GC-APCI-MS spectra 
beschreven. Deze database is voor iedereen toegankelijk via http://metams.lumc.nl. In deze 
database kan gemakkelijk gezocht worden op bijvoorbeeld de naam van een metaboliet, 
de molecuulformule of een KEGG nummer. Daarnaast is er de mogelijkheid om met MS 
spectra te zoeken gebruikmakend van de m/z-waarde en een gegeven tolerantie. De database 
bestaat uit zowel MS als MS2 spectra gecombineerd met de retentietijd indices zoals die uit 
de FID data zijn berekend. Op dit moment bevat de database gegevens van de belangrijkste 
metabolieten die in een lichaamsvloeistof aanwezig zijn (aminozuren, suikers, vetzuren, 
vitamines) maar het is de bedoeling dat deze, zoals iedere webtool, in de toekomst steeds 
wordt bijgewerkt. We hebben de database getest aan de hand van een  analyse van serum 
monsters. Echter, de analyse van dit soort monsters geeft altijd een verscheidenheid aan 
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moleculen die nog niet in de database staan. Om de identificatie hiervan te vergemakkelijken 
hebben we een protocol voor de novo identificatie geïmplementeerd.
In hoofdstuk 6, tenslotte, wordt GC-APCI-MS voor het eerst in een klinisch 
georiënteerd onderzoek toegepast. Hiervoor zijn de veranderingen in het urineprofiel van 
patiënten met UTI geanalyseerd. De multivariate statistische analyse gaf een duidelijke 
clustering van UTI-monsters t.o.v. de urinemonsters van dezelfde mensen die, op basis van 
een bacteriële kweek, na verloop van tijd hersteld waren. De in hoofdstuk 5 beschreven 
database maakte het mogelijk om de moleculen die ten grondslag lagen aan deze clustering 
op basis van zowel de spectra als de retentietijd te identificeren. Daarnaast konden enkele 
nieuwe metabolieten worden opgehelderd middels het nieuwe de novo protocol. De lijst 
van moleculaire descriptoren omvat zowel myo-inositol en citraat maar ook isomeren van 
hydroxyhippurinezuur. De fysiologische relevatie van hydroxyhippurinezuur blijkt onder 
andere uit studies waarbij het de aanwezigheid hiervan gekoppeld werd aan de remming van 
de Ca2+-ATPase tijdens de eindfase van patiënten met nierfalen. 
In dit deel van de studie werden verder de robuustheid en het dynamisch bereik van 
de FID detector getest met betrekking tot nieuwe mogelijkheden voor cross-platform data 
analyse methoden, voornamelijk in combinatie met NMR en LC-MS.
Dit proefschrift laat de complexiteit van het UTI-vraagstuk zien en geeft de 
complementariteit weer van verschillende analytische methoden die metabole veranderingen, 
die ten grondslag liggen aan fysiologische processen, zichtbaar kunnen maken. Elk van de 
analytische platforms gaf een unieke bijdrage aan het beschrijven van UTI-gemedieerde 
metabole veranderingen tijdens het infectieproces. De bepaling van bacteriële groei (NMR), 
de gastheer respons (LC-MS) en de fysiologische status (GC-APCI-MS) kunnen in de 
toekomst mogelijk een rol spelen bij het vaststellen van de hevigheid van de infectie en de 
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